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Quality of Life: Its Socio-Demographic and Genetic Determinants and Associations with Cancer 
Outcomes 
Jeanne A. Pierzynski, MPH 
Advisory Professor: Xifeng Wu, Ph.D., M.D. 
      Quality of life (QOL) is an independent prognostic factor for cancer. Lung cancer is the 
leading cause of cancer death. Breast cancer is the most diagnosed. Bladder cancer is the 
most expensive cancer to treat because of its high recurrence rate. We set to perform 
comprehensive analyses of predictors of QOL in these cancer sites with the future goal of 
improving QOL and outcomes.  
      In 6,456 newly diagnosed lung cancer patients, we investigated the relationship between 
baseline patient characteristics and QOL to identify determinants of QOL. A QOL questionnaire 
(SF-12v1) measured patients’ physical component summary (PCS) and mental component 
summary (MCS). Factors that were associated with mean PCS and MCS included smoking 
status (PCS Ptrend<0.001; MCS Ptrend<0.001) and education (PCS Ptrend<0.001; MCS 
Ptrend<0.001). Genetic factors were also analyzed (in the p38 MAPK pathway). The 
homozygous rare genotype of MEF2B: rs2040562 showed an increased risk of poor MCS (OR: 
3.06, 95% CI: 1.05-8.92, P=0.041). 
      Next, in 10,681 newly diagnosed breast cancer patients, we found that physical QOL was 
associated with higher risks of recurrence and death. We identified determinants of QOL such 
as marital status and tumor size. We found that Hispanics and Blacks reported lower PCS and 
the determinants of poor QOL were disproportionally more common in minorities.  
      Finally, we investigated the associations between genetic variants in the dopaminergic 
pathway and clinical outcomes in bladder cancer patients. This pathway is closely related to 
depression (a QOL domain) and depressive symptoms at diagnosis are associated with 
bladder cancer mortality. Using a two-stage design (discovery and independent validation), we 
vi 
 
identified several single nucleotide polymorphisms (SNPs) that was associated with recurrence 
or progression in non-muscle invasive bladder cancer overall or stratified by treatment.  
      In conclusion, we found important determinants of QOL in breast and lung cancer patients 
and racial disparities in breast cancer patients’ QOL. This may contribute to racial disparities in 
breast cancer outcomes. Genetic variations in QOL-related pathways may modulate bladder 
cancer outcomes. These results provide a framework for identifying cancer patients at high risk 
for poor QOL and poor clinical outcomes.  
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1.1. Overall Cancer Incidence and Mortality 
1.1.1. Cancer Incidence 
      The overall cancer incidence in the U.S. is decreasing(1). When examined by sex, it is 
decreasing in men and remaining stable in women(1). It is estimated that men’s cancer 
incidence has decreased approximately 2% per year based on the last decade of data(1). One 
reason for the decrease in cancer in men is thought to be due to decreases in PSA testing for 
men based on the U.S. Preventive Services Task Force recommendation because of the issue 
of over diagnosis and overtreatment of prostate cancer(2). Other potential reasons for the 
decrease in incidence in men are the decreases in diagnoses of lung and colorectal cancer(1). 
Women’s cancer incidence trends for lung and colorectal are also decreasing, but the rates for 
breast, uterine, melanoma, and thyroid are increasing or staying stable(1). The reducing 
incidence of colorectal cancer in both men and women is largely due to an increase in 
colonoscopies and the removal of precancerous adenomatous polyps(1, 3).  
1.1.2. Cancer Mortality 
      The overall mortality of cancer is also decreasing in U.S. This is seen across men and 
women, and a greater decrease is seen among the age group of 50-64 year olds(1, 4). Cancer 
mortality has decreased over the past two decades. This is due to the decrease in smoking 
rates and advances in cancer detection(1).  
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1.2 Lung Cancer 
1.2.1. Lung Cancer Incidence and Risk Factors 
      It is estimated that approximately 243,170 men and women will be diagnosed with 
respiratory system cancer in the United States, with 222,500 of those being lung cancer in 
2017(1). Slightly more men (116,990) than women (105,510) are estimated to develop lung 
cancer(1). It is the second most common cancer diagnosed in men and women(1). Lung 
cancer incidence is declining in men and women, but has declined approximately twice as 
quickly in men compared to women(1). This is mostly due to differences in smoking rates 
between men and women. Specifically, women began smoking later than men and at later 
ages and were slower to quit compared to men(5, 6).  
      The predominant risk factor for lung cancer is smoking and second hand smoke 
exposure(7). Men have higher incidences of lung cancer compared to women, and that is due 
to differences in tobacco usage(1, 8). Approximately 10-15% of lung cancer cases are in never 
smokers(9), which means there are other non-tobacco related risk factors. One such factor is 
radon exposure. Radon exposure is of concern to the general public due to indoor exposure 
and the potency of radon even when exposed to even small amounts(8). Certain occupational 
exposures also are risk factors for lung cancer. Asbestos exposure is a significant risk factor for 
lung cancer, as well as other occupational exposures such as arsenic and potentially silica(8, 
10, 11). In addition, outdoor air pollution has been linked to increased lung cancer risk(8). This 
association is thought to be stronger in non-smokers(12, 13). Finally, there may be an 
association between diet and lung cancer risk. A recent study found that a diet with a high 
glycemic load or glycemic index (foods that cause a spike in blood sugar) was associated with 
an increased risk of lung cancer in non-Hispanic Whites. This association was seen stronger in 
non-smokers and patients with squamous cell carcinoma(14).  
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1.2.2 Lung Cancer Histology and Treatment 
      Lung cancers are typically classified in two categories: Non-small cell lung cancer (NSCLC) 
and small cell lung cancer (SCLC). NSCLC accounts for 85% of all lung cancer diagnoses. 
Histology of NSCLC includes adenocarcinoma, large cell carcinoma, squamous cell carcinoma, 
and bronchioalveolar carcinoma(15). Approximately 13% of lung cancer diagnosed are 
SCLC(16), which also has a very poor prognostic outlook(15). Other rare types of lung cancer 
include mesothelioma and carcinoid tumors. 
      Treatment options vary depending on the type of lung cancer. SCLC patients usually 
receive chemotherapy with some going on to receive radiation therapy(16). For patients with 
stage I or stage II NSCLC, approximately 69% of patients receive surgery(16), with 25% of 
those patients going on to receive chemotherapy and/or radiation(16). NSCLC patients 
diagnosed with stage III or stage IV disease receive chemotherapy with some going on to 
receive radiation as well(16). Depending on the genetic mutations present in NSCLC patient’s 
tumor, targeted therapy is an option as well. Potential targeted therapies include anaplastic 
lymphoma kinase (ALK) inhibitors and epidermal growth factor receptor (EGFR) inhibitors(16). 
Recent immunotherapies have also been developed that can be beneficial for NSCLC 
patients(16).   
1.2.3. Lung Cancer Prognostic Factors and Clinical Outcomes 
      Lung cancer is a very deadly disease. Lung cancer survival depends on the stage at 
diagnosis. Patients diagnosed with localized disease from 2003 to 2009 had a five-year survival 
rate of 54% and that dropped down to 26% for regional stage and a dismal 4% for metastatic 
disease(17). When examining NSCLC and SCLC, SCLC has a five-year survival rate of 7% 
and NSCLC’s five-year survival rate is 21%(16).  
      Prognostic factors can be grouped into two groups: clinical and host factors. Also, 
prognostic factors differ for different types of lung cancer. Clinical prognostic factors for NSCLC 
include poorly differentiated or undifferentiated carcinoma (poor survival), tumor genetic 
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markers such as EGFR or HER2 mutations (mutations that can be targeted for therapy which 
leads to better survival), the presence of metastasis, and ≥4 metastatic sites involved(18-20). 
Host characteristic prognostic factors for NSCLC include never smoking, age, sex (female sex 
is predictive of better survival), and performance status (a better performance status is 
predictive of better survival)(18, 20-22). Further, GWAS studies have shown promising results 
with variants showing association with survival in never smokers with NSCLC(23, 24). Recent 
research has also examined health-related quality of life (QOL) as a predictor of NSCLC lung 
cancer survival with promising results. A better QOL at time of diagnosis or within 6 months of it 
has been associated as an independent prognostic factor in lung cancer survival(25, 26) and is 
considered an important part of a lung cancer patient’s comprehensive treatment plan. When 
examining prognostic factors for SLCL, extent of disease, sex, and performance status are 
independent factors for survival of SCLC(27, 28). Research has focused some on genetic 
predictors of survival, but the majority of this work has focused on NSCLC. Recently, the 
germline variant rs942190 in TDPI was associated with poor survival in SCLC patients(29).  
1.3 Breast Cancer 
1.3.1. Breast Cancer Incidence and Risk Factors 
      Breast cancer is the number one cancer diagnosed in women and the number two cause of 
cancer-related death in women, with approximately 252,710 women being diagnosed and 
40,610 dying from the disease in the U.S. in 2017(1). The majority of breast cancers are 
diagnosed in women over the age of 59 (81%) and 89% of breast cancer deaths occur in this 
age range(30). Incidence rates increased in the 1980’s and 1990’s due to the increase in use of 
mammography screening and it is believed that those rates were inflated. A decrease in 
incidence was seen in the early 2000’s due to a decrease in hormone therapy taken by 
menopausal women(30-33). The median age of diagnosis in women is 62 years of age and the 
median age of breast cancer death is 68 years of age(30). When examining racial disparities in 
breast cancer, Black women are diagnosed at a median age of 59, while white women are 
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diagnosed at an older median age of 63(30). The median age of breast cancer death in Black 
women is much lower than that in white women (62 years vs. 70 years). Black women show a 
lower incidence rate of breast cancer, but a higher mortality rate compared to non-Hispanic 
White women(30). 
      There is a significant amount of research that has examined risk factors for breast cancer. 
A seminal study from the Women’s Health initiative found that estrogen use paired with 
progesterone as hormone therapy in menopausal women was a major risk factor for breast 
cancer(31). Reproductive factors associated with an increased risk of breast cancer include 
early age of menarche, late age of menopause, and nulliparity or later age at first 
pregnancy(34). Risk of breast cancer also increases as a women ages and it is estimated that 
a women’s risk doubles every ten years until menopause(34). Mutations in genes BRCA1 and 
BRCA2 play a major role in many breast cancer cases in families with significant history of 
breast cancer(34). Finally, body mass index (BMI) (specifically obese and overweight women) 
is associated with an overall increased risk of breast cancer and this is consistently seen in 
postmenopausal women. Conflicting results have been shown in premenopausal women. Most 
studies have shown an inverse relationship between obesity and breast cancer risk in 
premenopausal women(35-37), but one study showed obesity as a risk factor in this same 
group(38). The inverse relationship in premenopausal women between BMI and breast cancer 
risk was only observed in Caucasian and Black women, but not Asian women, in whom there 
was a positive association between obesity and breast cancer risk(39).  
1.3.2. Breast Cancer Molecular Subtype and Treatment 
      It is widely known that breast cancer is a very heterogeneous disease. Breast cancer is 
typically divided into two major molecular subtype groups: basal-like tumors and luminal A, 
luminal B, and HER2 enriched tumors(40). Basel-like tumors grow from basal/myoepithelial 
compartments and luminal A, luminal B, and HER2 enriched tumors grow from luminal cellular 
compartments(40). To further differentiate breast tumors, luminal A and luminal B tumors are 
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either estrogen receptor positive (ER-positive) and/or progesterone receptor positive (PR-
positive). Further, luminal B tumors can also be HER2 positive(40). Basal-like tumors include 
triple-negative tumors which lack receptors for estrogen, progesterone, and HER2(40). Racial 
disparities also exist in terms of molecular subtype: premenopausal African Americans are 
more likely to be diagnosed with basal-like tumors (such as triple-negative, which have worse 
outcomes) and less likely to be diagnosed with luminal A tumors (which have a more favorable 
outcome)(41).  
      Women with local or regional breast cancer typically receive surgery (either breast 
conserving surgery or a mastectomy) followed by radiation therapy(16). Patients who are more 
likely to receive a mastectomy are those who have more advanced/aggressive tumors, are 
younger than the age of 40, or because radiation post-surgery is not recommended due to a 
previous condition(16, 42, 43). The majority of women with Stage III breast cancer will undergo 
a mastectomy instead of breast conserving surgery. Women diagnosed with Stage IV breast 
cancer receive chemotherapy and/or radiation(16). If a women has a hormone receptor positive 
tumor, most (79%) will receive hormone therapy(16).  
1.3.3. Breast Cancer Prognostic Factors and Clinical Outcomes 
      Much of the research on predictors of breast cancer recurrence focus on molecular aspects 
of breast cancer. For example, women with triple-negative breast cancer have a higher risk of 
relapse and death within five years of diagnosis(44) and luminal A tumors tend to have better 
outcomes and lower rates of local or regional recurrence(45). In women with stage I or II breast 
cancer, vascular invasion from the tumor is associated with increased risk of local 
recurrence(46). Women with Stage I or II invasive breast cancer have a higher risk of 
recurrence if positive margins were found during surgery to remove the tumor(47). And high-
grade tumors also are associated with a higher risk of recurrence following breast conserving 
surgery(48). When examining patient characteristics, age is a strong predictor of 
recurrence(49). One study found that women diagnosed with early stage breast cancer at 
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younger than the age of 35 showed a higher risk of recurrence(50). Racial disparities exist as 
well with recurrence of breast cancer. African American women are at a higher risk of 
recurrence compared to white women(51, 52). 
      There has been substantial research done on predictors of survival in breast cancer 
patients. Two of the most significant prognostic factors are tumor size and lymph node 
status(53). Other major prognostic factors include estrogen receptor/progesterone receptor 
status, with the presence of the receptors correlating with better survival(54, 55). Some 
research suggests that the effect of hormone receptor on survival is not long term and this may 
be due to the positive receptor status causing breast tumors to grow slower(56). Another major 
prognostic factor is the overexpression of HER2/neu in breast tumors. Overexpression of 
HER2/neu is associated with a more aggressive breast tumor, higher rates of recurrence, and 
higher rates of death in patients with positive lymph node tumors(57). Finally, recently 
published studies also include prognostic models for potential predictors of recurrence and 
survival of breast cancer(58). 
      Recurrence rates differ based on type of breast cancer and treatment. For example, women 
with breast cancer who received breast-conserving therapy only had a 10-year risk of 
locoregional or distant recurrence rate of 35%, and with receiving radiation therapy that risk 
decreased to 19.3%(59). When examining specific subtypes of breast cancer, triple-negative 
breast cancer has a significant increased risk of recurrence within the first five-years(44). 
Breast cancer survival rates have been improving. From 1989 to 2014, the death rate 
decreased by 38% for breast cancer(1). Women diagnosed with localized disease have a five-
year survival rate of 99%(1). When the disease is diagnosed regionally, that percentage drops 
to 85%(1). And women diagnosed with distant disease have a five-year survival rate of 26%(1). 
When examining racial disparities in breast cancer survival, Asian/Pacific Island (PI) women 
have the highest five-year breast cancer survival (overall and for each stage at diagnosis). And 
Black women have the lowest five-year breast cancer survival. When looking at mortality trends 
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by race, from 2003-2012 breast cancer mortality rates declined by 1.8% in whites, 1.5% in 
Hispanics, and 1.0% in Asian/PI (60).  
1.4. Bladder Cancer 
1.4.1. Bladder Cancer Incidence and Risk Factors 
      Bladder cancer is a cancer that affects men more than women and incidence and death 
rates are approximately four-fold higher in men(1). This makes it the estimated fourth most 
diagnosed cancer and the eighth cause of cancer related death in men in the U.S. in 2017. 
Approximately 60,490 men will be diagnosed and 12,240 men will die from the disease(1). 
Bladder cancer incidence rates have been consistent over time. 
      The most significant environmental and modifiable risk factor for bladder cancer is 
smoking(61-63). Another established environmental risk factor for bladder cancer is 
occupational exposures to aromatic amines(64). A family history of bladder cancer is also a risk 
factor(65), and family members with a first-degree relative diagnosed have a two-fold increased 
risk of developing the cancer(66). Genetic variations in candidate genes have been recognized 
as risk factors as well. For example, NAT2 slow acetylator genotype has been found to 
increase the risk of bladder cancer by 40%(67, 68). Also, it is well recognized that the GSTM1-
null phenotype is associated with an increased risk of bladder cancer(67, 69). Single nucleotide 
polymorphisms (SNPs) in several genes have also been associated with susceptibility to 
bladder cancer. For example, rs2294008 in PSCA located on 8q24.3 was discovered via a 
genome-wide association study (GWAS) and was associated with a 1.15-fold increased risk of 
bladder cancer (OR=1.15, 95% CI: 1.10-1.20, P=2.14x10-10)(70). Other variants associated 
with bladder cancer susceptibility include MYC: rs9642880, TP63: rs710521, FGFR3: 
rs798766, CLPTM1L: rs401681, TERT: rs2736098, rs1014971, CCNE1: rs8102137, and 
UGT1A: rs11892031(67).  
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1.4.2. Bladder Cancer Histology and Treatment 
      The majority of bladder cancers diagnosed in Western nations are urothelial carcinomas 
(transitional cell carcinoma)(67). Bladder cancer can be broadly categorized as non-muscle 
invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC). NMIBC is bladder 
cancer that has not invaded the muscle layer of the bladder and MIBC has invaded the muscle 
layer of the bladder(71).  
      Standard treatment for patients diagnosed with NMIBC is transurethral resection (TUR). 
Typically TUR is followed with intravesical chemotherapy such as Bacillus Calmette-Guerin 
(BCG)(72, 73) with the goal of preventing or delaying recurrence or progression of disease. 
Patients diagnosed with MIBC typically have a cystectomy and then receive chemotherapy 
and/or radiation(74).  
1.4.3. Bladder Cancer Prognostic Factors and Clinical Outcomes 
      NMIBC and MIBC have common and distinct prognostic factors. For NMIBC, factors that 
are considered predictors of recurrence and/or progression are tumor size, number of tumors, 
prior recurrence rate, T category, grade, presence of carcinoma in situ(75). For patients with 
MIBC, prognostic factors include small tumor size, papillary histology, absence of 
hydronephrosis, a complete response to induction chemotherapy, and a complete TUR that is 
visible(76). 
      Patients with NMIBC face a high risk of recurrence, as 50-80% of patients experience a 
recurrence(77). Of those patients, approximately 14% go on to progress to MIBC after 
receiving TUR(77) and overall 20-30% of NMIBC progress to a higher grade or stage(71). This 
indicates that the majority of patients diagnosed with MIBC are diagnosed without a prior 
history of superficial diasease(78). When analyzing survival statistics in bladder cancer 
patients, survival statistics are divided by NMIBC and MIBC. NMIBC patients fare well in terms 
of survival. Patients who are diagnosed with NMIBC low-grade disease Ta do not have a 15-
year cancer-specific mortality(79, 80). Patients diagnosed with high-grade Ta tumors have a 
15-year disease specific survival of 74%(79, 80). Patients diagnosed with T1 tumors have a 15-
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year disease specific survival of 61%(79, 80). When examining MIBC survival statistics, the 
outlook is not as favorable. Patients with MIBC have a 50% five-year survival rate after 
cystectomy(81). If a patient has a T3 (has invaded into the fatty layer outside of the bladder) or 
T4 (spread locally beyond the bladder) tumor, the five-year survival decreases to between 25-
35%(81). 
1.5 Quality of Life 
1.5.1. Quality of Life Overview 
      QOL has become increasingly important for cancer patients and their treatment. It is a 
comprehensive concept that spans many domains of a patient’s well-being. QOL is subjective 
and includes cognitive, psychosocial, emotional, spiritual, social, and physical domains 
domains(82). When patients are faced with a diagnosis of cancer, psychosocial stress is a 
major product of the diagnosis and it is expected that changes in QOL will occur, but a new 
cancer diagnosis does not account for all the inter-individual variation in QOL that is seen in 
newly diagnosed cancer patients(82, 83). QOL is important to understand because it can lead 
to meaningful clinical changes in cancer patients(84).  
1.5.2. QOL Measures 
      Quality of life is measured by a validated questionnaire. There are many measures for 
quantifying QOL, including questionnaires that measure general QOL in many populations(85) 
or are disease specific (such as cancer)(86).Research has supported that there is no difference 
in responsiveness or accuracy of capturing QOL changes between using general 
questionnaires or disease specific(87). One questionnaire that is used for many different 
populations is the Short-Form 12 version 1 (SF-12v1). The SF-12v1 is a 12 question measure 
that was derived from the SF-36 questionnaire(88). It encompasses four domains of QOL 
(physical, social, functional, and emotional) and eight subscales (physical functioning, general 
health, bodily pain, role physical, vitality, social functioning, role emotional, and mental 
health)(89). When scored, the questionnaire is normalized to a mean of 50, which is based on 
the US general population. A higher score indicates a better QOL.  
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1.5.3. Determinants of QOL 
      Patient determinants (host and clinical) can impact a patient’s QOL(83, 90, 91). Few 
studies have examined QOL in a group comprised of many cancer sites. For example, a study 
comprised of 351 patients (with approximately 9% of patients currently undergoing 
chemotherapy or radiation) with breast, gynecologic, urologic, and gastrointestinal cancers 
examined determinants of QOL(83). This study discovered that when examining physical QOL 
domains, patients who were men, did not have recurrent cancer, and were not in active 
treatment reported better physical QOL(83). When examining mental QOL, patients who had 
good social support, a higher education level, were older, married, and did not have advanced 
disease reported better mental QOL(83).  
      Many studies have examined specific cancer sites. For example, patients who continue to 
smoke cigarettes after being diagnosed with advanced lung cancer report worse QOL 
compared to patients who quit smoking cigarettes after diagnosis(92). Another study from 
Mayo Clinic examined marital status and QOL in lung cancer patients. While marital status at 
diagnosis was not associated with QOL overall, there were interesting associations when 
examining specific domains of QOL(90). Specifically, patients that were widowed and married 
at diagnosis scored better on social support and spirituality than single and divorced 
patients(90). Another study examining QOL in 101 newly diagnosed lung cancer patients 
(within three months of their diagnosis) found that self-efficacy was a strong predictor of 
QOL(93). Many of the studies published on QOL in lung cancer patients are plagued by small 
sample sizes and lack of detailed demographic data. To our knowledge, there currently lacks 
an in-depth comprehensive analysis of determinants of QOL in newly diagnosed lung cancer 
patients.  
      There are many studies that examined predictors of QOL in breast cancer patients, though 
many examined QOL issues in long-term breast cancer survivors. A prospective study using 
the survivors of breast, colorectal, and endometrial cancer in the Iowa Women’s Health Study 
established that persistent smokers were more likely to report poor physical functioning(94). A 
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study examined how QOL changes throughout treatment and found that women who were less 
than 60 years of age or had a psychiatric morbidity were more likely to report poor QOL at 
diagnosis before treatment(95). Another study also found that younger age (<50) was 
associated with poor QOL(96). Racial disparity in breast cancer patients is an important issue 
and this issue expands into QOL. For example, African American breast cancer survivors are 
more likely to report poor physical function compared to Caucasian patients in unadjusted 
models(97). This is thought to be attenuated by factors such as BMI(97). In a comprehensive 
study that examined QOL differences among races, lower acculturated Latinas had lower 
functional well-being and emotional well-being (domains of QOL) compared to Whites. And 
African Americans reported better emotional well-being compared to Whites(96). While 
research supports racial disparities in QOL in breast cancer patients, more research is needed 
to understand predictors of this disparity.  
      Recent research has suggested that depression (a domain of QOL) is an important 
component of survival in cancer patients(98). It is estimated that the prevalence of depression 
in cancer patients rages from 13% to 40% and that a significant number of patients have 
depressive symptoms without meeting the threshold criteria for depression(98, 99). Depression 
and anxiety can lead to poor outcomes after surgery and hinder post-surgery healing(100). 
When looking at cancer specific studies, current depressive symptoms at time of bladder 
cancer diagnosis was associated with poor overall survival(101). And studies suggest that up to 
42% of bladder cancer patients report depression(102, 103). The mechanism behind this 
finding is not clearly understood but is hypothesized that increased mortality could be related to 
neuroendocrine and immunological mechanisms(101, 104, 105). 
1.5.4. Genetic Predictors of QOL 
      Research supports a genetic component to QOL in cancer patients. A majority of the work 
has been done in lung cancer populations. A study from Mayo clinic analyzed 470 SNPs in 56 
genes(106). A total of six SNPs on four genes were validated and associated with QOL and 
QOL domains in lung cancer patients in adjusted and unadjusted models (MGMT: rs38538300, 
14 
 
MGMT: 10741191, MGMT: rs3852507, GSTZ1: rs2287396, ABCC4: rs9524885)(106). Another 
study examined genetic variants and the association with pain severity in lung cancer 
patients(107). This study found that a variant in IL-8 was associated with significant pain in 
white lung cancer patients(107). Finally, another study examined QOL and pro- and anti-
inflammatory cytokine genetic variants in a mixed cancer population (breast, lung, and 
brain)(108). The results suggested that SNPs in interleukin 1 receptor 2 (IL1R2) were 
associated with lower QOL (when QOL was dichotomized as high and low) and SNPs in 
nuclear factor kappa beta 2 (NFKB2) were also associated with lower QOL(108). Inflammatory 
related pathways are an important area to examine when examining genetics and QOL in 
cancer patients because the biologic mechanism of inflammation is an important part of QOL 
as well as cancer clinical outcomes(109-111). For example, increased circulating levels of pro-
inflammatory cytokines have been found in newly diagnosed cancer patients. These increased 
levels of cytokines can pass into the central nervous system (CNS) and cause increased 
psychobehavioural symptoms such as fatigue and depression which can negatively impact 
QOL(111). Further, activation of inflammatory pathways, such as the p38 MAPK pathway, can 
alter neurotransmitter function in the CNS which can have negative impacts of domains of QOL 
such as depression(112).  
      Another area of research focus is in genetics and domains of QOL, like depression. 
Depression is an important component of QOL in cancer patients. As discussed above, the 
study regarding depressive symptoms in newly diagnosed bladder cancer patients and overall 
survival lead to the question “Could there be a genetic component to these findings?”(101). A 
pathway of interest to examine genetic predictors of depression and poor clinical outcomes in 
bladder cancer patients is the dopamine pathway. There are four main dopamine pathway in 
the brain: Nigrostriatal, mesolimbic, mesocortical, and tuberoinfundibular(113). Dopamine is 
synthesized from tyrosine in the cytoplasm of presynaptic neurons and when released 
dopamine interacts with one of five dopamine receptors in the postsynaptic neuron(114). The 
dopamine receptors are divided into two groups: the dopamine 1 (D1) family which is made up 
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of D1 and D5 subtypes and the D2 family (made up of D2, D3 and D4 subtypes). The D1 
receptors increase intracellular cyclic adenosine monophosphate (cAMP) concentrations and 
also activate secondary messenger pathways(114). The D2 family reduces adenylate cyclase 
activity and can assist in controlling release of dopamine(114). The dopamine system plays 
many roles that are vital to human function such as voluntary movement, feeding, affect, sleep, 
reward, and working memory(113). Dopamine also functions in the periphery and regulates 
renal function and cardiovascular functions among other systems(115). Mental health disorders 
such as depression, schizophrenia, attention deficit hyperactivity disorder (ADHD), and bi-polar 
depression are associated with the dopamine system(113, 114). The association with 
depression is what makes this pathway of interest for this current study as well as the evidence 
of dopamine receptor expression in the bladder wall (DRD1 and DRD2)(116).  
1.5.5. QOL and Survival in Cancer Patients 
      One reason that QOL is so important in cancer patients is because of the association 
between QOL and survival. Specifically, QOL is considered a prognostic indicator in cancer 
patients, with a better QOL associated with better survival(117). This has been seen in 
populations of mixed cancer types(117) as well as cancer site specific studies(118-121). The 
importance of QOL as a prognostic factor for survival in cancer patients is that interventions 
can be targeted to improve QOL with the hopes of improving survival and improving the 
patient’s cancer experience. An example of one such intervention was done in patients with 
advanced cancer receiving radiotherapy(82). The QOL intervention arm of this trial saw 
significant improvements in QOL scores compared to the group that did not receive the 
intervention(82). This highlights the importance of understanding the complicated subject of 
QOL in cancer patients.  
1.6 Hypotheses 
The work was conducted with the following hypotheses in mind:  
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Hypothesis I: QOL varies by demographic and clinical characteristics in newly diagnosed lung 
cancer patients. 
 
Hypothesis II: To determine the association between QOL and survival in breast cancer 
patients as well as characterize determinants of QOL among racial groups in breast cancer 
patients. 
 
Hypothesis III: To determine the association between genetic variants in a pathway involved in 
inflammation and depression and QOL in a subset of newly diagnosed cancer patients. 
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Chapter 2. Socio-demographic, Clinical, and Genetic Determinants of 
Quality of Life in Lung Cancer Patients 
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2.1. Introduction 
      Newly diagnosed lung cancer patients experience one of the worst symptom burdens(122). 
Symptom burden and poor prognosis underscore the need to better understand the mediating 
factors that impact both and the potential relationship among the two adverse outcomes. In 
recent years, health-related quality of life (QOL) has become an important aspect of cancer 
treatment and research has linked improved patient-reported QOL to improved lung cancer 
survival(121, 123).   
      To date, several studies have investigated the role of demographic factors on QOL in 
cancer patients. For example, African American men recently diagnosed with prostate cancer 
and African American women breast cancer survivors reported better emotional well-being 
compared to Caucasians(96, 124). Older age has been shown to be a strong predictor of 
emotional and physical well-being for a variety of cancer sites, including late-stage 
gastrointestinal, genitourinary, breast or gynecological cancer, lung, pancreatic, or esophageal 
cancer (125).  
      Previous studies suggested that women with lung cancer report higher rates of depression 
prior to treatment (49%) than men (29%), and that depression is a strong indicator of QOL(126, 
127). In small cell lung cancer (SCLC)  patients, one study showed that late quitters (those 
smoking one year post diagnosis) exhibited the worst QOL compared to all other smoking 
categories(128), while another study reported inconsistent findings with persistent smokers 
(those who continue to smoke following diagnosis) reporting worse QOL(129). While evidence 
suggests that demographic characteristics are predictors of cancer patient QOL, inter-individual 
variability still remains, which may be explained by clinical factors. For example, SCLC patients 
reported worse depression and anxiety than non-small cell lung cancer (NSCLC) patients(126).  
      Genetic components may also affect QOL and therefore impact survival in lung cancer 
patients. However, there are a limited number of studies that have explored this hypothesis in 
lung cancer. For example, one study reported an association between three single nucleotide 
polymorphisms (SNPs) in two genes related to inflammation (LTA and PTGS2) and pain 
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severity, social functioning, and mental health in 3-5 year lung cancer survivors(130). The p38 
MAPK pathway is activated through extracellular stimuli such as pro-inflammatory cytokines 
including interleukin (IL)-1) and tumor necrosis factor (TNF) alpha(131). Once the p38 MAPK 
pathway is activated, the downstream effects ultimately result in changes in cell survival 
through programmed cell death(132) and pathway activation can lead to the increased 
production of more pro-inflammatory cytokines(133). This pathway is of interest in regards to 
QOL because it is a key mediator of response to cellular and environmental stress. Examples 
of stress that activate this pathway are pro-inflammatory cytokines (as stated above, such as 
IL-1 and TNF-alpha (which can then produce more pro-inflammatory cytokines)), which have 
been associated with negative symptoms in cancer patients (such as fatigue and depression) 
of which can negatively impact QOL(111). To date, no study has examined genetic variation in 
this pathway in relation to QOL in lung cancer patients. 
       Since 1999, lung cancer patients at MD Anderson Cancer Center have completed the SF-
12 general health-related QOL questionnaire at their first clinic visit, providing an opportunity to 
systematically investigate the factors that contribute to variation in QOL at diagnosis in a large 
group of lung cancer patients. The availability of DNA for genetic analyses and extensive 
clinical and follow-up information also allowed for assessment of the role of genetic variation on 
QOL and relationship with survival. The findings provide a better understanding of baseline 
QOL factors affecting lung cancer patients and potentially set the stage for behavioral 
interventions to improve both QOL and survival. 
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2.2. Methods 
2.2.1. Study Population  
      The population for the current analysis included 6,420 newly diagnosed lung cancer 
patients with a diagnosis of a tumor of the lung according the World Health Organization 
(WHO) classification (this includes SCLC and NSCLC) from The University of Texas MD 
Anderson Cancer Center. Study participants included those that completed an institutional 
patient health intake questionnaire at their initial visit to MD Anderson within one year of 
diagnosis.  
      For exclusion criteria, individuals with multiple primary tumors were excluded, except for 
multiple lung tumors. The participants provided written informed consent and the study was 
approved by the Institutional Review Board. 
2.2.2. Data Collection 
      The SF-12v1 is part of MD Anderson’s institutional patient intake questionnaire completed 
by all new patients at MD Anderson Cancer Center, which also includes demographic and 
epidemiological data. The SF-12v1 had 8 subscales that are measured (physical functioning, 
role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental 
health), and these subscales were used to calculate the Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scores(89). Both the MSC and PCS were normalized 
to a mean of 50 (SD=10) based on responses to the SF-12v1 among the US general 
population. A higher score (greater than 50) indicated a QOL that is better than the general 
population. The question in the SF-12v1 that asks “During the past 4 weeks, how much did 
pain interfere with your normal work” was modified in our patient intake questionnaire as 
“During the past week, has pain interfered with your general activities” and the scoring was 
adjusted to match the SF-12v1 scoring.  
      Race was self-reported by the study participants. Race was classified as “White, Anglo”, 
“Hispanic Origin” “Black” “Asian/Pacific Islander” and “Other”. Smokers were classified into 
three groups: “never”, “yes, but quit”, and “yes, currently” and was self-reported. Never 
21 
 
smokers were defined as individuals who had smoked less than 100 cigarettes in their lifetime. 
Alcohol usage was divided into three groups: never, former and current drinkers (having one or 
more drink per week). Participants had a positive past medical history if they self-reported a 
previous diagnosis of heart or lung problems, diabetes, high blood pressure, liver problems, 
thyroid problems, kidney problems, frequent infections, stroke, bleeding problems, HIV/AIDS, 
seizures, circulation problems, and any psychological or psychiatric problems.  
      Pathological features, treatment, and survival data were obtained from MD Anderson’s 
Tumor Registry for all study participants. 
2.2.3. DNA Isolation and Genotyping  
       A subset of patients (N=641) were previously enrolled in an ongoing lung cancer 
epidemiology study which allowed us to analyze 218 SNPS in 20 genes from the p38 MAPK 
pathway. DNA isolation and genotyping methods have been previously described(134, 135). In 
short, inflammation pathway-related genes were identified through the Gene Oncology 
Database(136, 137) and the National Center for Biotechnology Information (NCBI) 
Pubmed(138). Haplotype tagging SNPs were selected for each gene 10 kb upstream of the 
transcriptional start site or 10 kb downstream of the transcriptional stop site. SNPs in the 
coding (nonsynonymous SNPs and synonymous SNPs) and regulatory regions (splicing site, 
promoter, 5’UTR, and 3’UTR). In addition, SNPs previously reported to be associated with 
cancer and functional SNPs were included. Genotyping was completed using the Illumina 
Infinium iSelect HD Custom Genotyping BeadChip.  
2.2.4. Statistical Analysis 
      To analyze the difference in mean PCS and MCS scores between categories of host 
characteristics, t-test or ANOVA with pairwise comparison testing was used (SIDAK test). PCS 
and MCS were dichotomized by 50 (previously established cut-off) to assess the association of 
demographic and clinical variables with QOL. Unconditional multivariate logistic regression was 
used to calculate odd ratios (ORs), 95% confidence intervals (CIs), and P values. Confounders 
were adjusted for in the PCS and MCS multivariable models and included age, sex, education 
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level, race, marital status, alcohol use, smoking status, history of past medical event, histology, 
cancer stage, and prior treatment for current or previous cancer. A sensitivity analysis was 
completed and found no major differences between the full data (with missing stage 
categorized as unknown) and the reduced data (with missing stage removed) (data not shown). 
Therefore, the full dataset was used. For the effect of 218 SNPs in the p38 MAPK pathway on 
PCS and MCS risk, multivariate unconditional logistic regression was used to estimate ORs 
and 95% CIs. Dominant, recessive, and additive models of inheritance were assessed for each 
SNP. The study sample was divided into two groups by assigning alternating samples into the 
discovery set and the validation set, with the first group analyzed in a discovery phase and the 
significant variants from the discovery phase were checked for validation in the second group 
as validation phase (adjusting for the same factors as described above). Multivariate Cox 
regression was used to estimate hazard ratios (HR) and 95% CI for all survival analyses. The 
proportional hazards was examined by graphing log(-log(survival)) versus log of survival time. 
The effects of PCS and MCS scores on five-year lung cancer survival (calculated using the 
diagnosis date and last contact date) were estimated, adjusting for age, sex, race, smoking 
status, histology, cancer stage, prior cancer treatment, and treatment at MD Anderson. Kaplan-
Meier survival curves and log-rank tests were calculated to analyze the difference in five-year 
survival times between PCS and MCS scores and stage. The association between genetic 
variants in the p38 MAPK pathway and five-year survival was calculated in the dominant, 
recessive, and additive models of inheritance, adjusting for age, sex, smoking status, histology, 
stage, surgery (yes/no), radiation (yes/no), chemoradiation (yes/no), and pre-treatment 
performance status. Additional factors were adjusted for in the genetic survival analysis 
because data was available for those covariates. Discovery and validation analyses were 
completed as described above. Statistics were completed using STATA 13 (Stata Corporation, 
College Station, TX) statistical software. A P value of less than 0.05 was considered statistically 
significant. VEGAS software was used to perform a gene-based interaction analysis(139). A P 
value of <0.05 was significant. In the VEGAS analysis, significant variants were carried forward 
23 
 
and the validation set was analyzed using the same model that was most significant in the 
discovery phase.  
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2.3. Results 
2.3.1. Host Characteristics 
      The patient characteristics are shown in Table 1. The majority of the patients were 60 to 69 
years of age, with a mean age of 60.9 years. Most patients were married (72.9%) and had 
completed at least a high school education (57.7%). White patients made up the largest racial 
group. Among the smoking status groups, 1,112 patients were never smokers, 4,083 patients 
were former smokers and 1,197 patients were current smokers. Also, most patients reported 
never consuming alcohol (41.2% of patients). In addition, 621 patients were diagnosed with 
stage I lung cancer, 228 were diagnosed with stage II, 979 were diagnosed with stage III, and 
1,768 patients were diagnosed with stage IV lung cancer. The distribution of PCS and MCS 
scores in the study population is seen in Figure 1. The distribution of PCS and MCS scores in 
the study population show that neither the PCS nor MCS scores are normally distributed. The 
patient characteristics for the sub population that are part of the on-going lung cancer 
epidemiology study with genetic information is seen in Table 2.  
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Table 1. Host Characteristics and the Association of Demographic, Lifestyle, and Clinical 
Characteristics with PCS and MCS Score 
Characteristic  N 
% 
PCS, Mean (SD) P value 
MCS, Mean 
(SD)  
P value 
Age       
<50 1,081 16.84 39.05 (11.60)  45.37 (10.89)  
50-59 1,672 26.04 39.12 (11.95) 1.000 44.57 (11.33) 0.351 
60-69 2,149 33.47 38.50 (11.93) 0.759 46.23 (11.35) 0.221 
70+ 1,518 23.64 38.44 (11.59) 0.715 47.48 (11.45) <0.001 
P for trend    0.066  2.1x10-10 
Sex       
  Male 3,431 53.46 38.96 (11.90)  46.75 (11.33)  
  Female 2,987 46.54 38.49 (11.69) 0.109 45.03 (11.29) <0.001 
Marital status       
Married 4,679 72.93 39.24 (11.75)  46.33 (11.19)  
Widowed 635 9.90 37.00 (11.73) <0.001 45.83 (11.84) 0.972 
Separated 34 0.53 36.06 (11.91) 0.710 42.19 (11.27) 0.290 
Divorced 637 9.93 37.24 (11.64) 0.001 44.13 (11.66) <0.001 
Never Married 431 6.72 38.23 (12.30) 0.606 44.96 (11.37) 0.154 
Education       
<High School 760 12.37 35.17 (11.22)  42.63 (11.81)  
High 
School/Vocational/AA 
3,543 57.66 38.02 (11.60) <0.001 45.85 (11.45) <0.001 
College Degree 1,842 29.98 41.77 (11.71) <0.001 47.64 (10.59) <0.001 
P for trend    1.1x10-46  7.1x10-24 
Race       
White 5,268 83.09 38.92 (11.75)  45.97 (11.34)  
Hispanic 280 4.42 39.05 (11.73) 1.000 44.56 (11.71) 0.355 
Black 460 7.26 35.73 (11.97) <0.001 45.21 (11.40) 0.849 
Asian/Pacific Islander 217 3.42 40.62 (11.54) 0.316 48.26 (10.68) 0.034 
Other 115 1.81 37.80 (12.21) 0.976 47.27 (10.90) 0.918 
Alcohol       
Never 2,626 41.19 37.19 (11.50)  45.48 (11.58)  
Former 1,205 18.90 35.37 (11.21) <0.001 44.48 (11.58) 0.033 
Current 2,544 39.91 41.93 (11.64) <0.001 47.14 (10.86) <0.001 
P for trend    2.3x10-47  1.6x10-7 
Smoking       
Never 1,112 17.40 40.78 (11.86)  48.02 (10.51)  
Former 4,083 63.88 38.85 (11.73) <0.001 46.06 (11.29) <0.001 
Current 1,197 18.73 36.47 (11.65) <0.001 43.61 (11.88) <0.001 
P for trend    1.2x10-18  5.4x10-21 
Past Medical History       
Yes 5,394 84.43 38.37 (11.78)  45.81 (11.45)  
No 995 15.57 40.61 (11.80) <0.001 46.73 (10.66) 0.018 
Past Cancer Treatment       
Yes 1,845 28.74 35.86 (10.62)  45.39 (11.15)  
No 4,575 71.26 39.90 (12.06) <0.001 46.17 (11.41) 0.012 
Histology       
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Non-Small Cell 
Carcinoma 
 
 
    
Adenocarcinoma 2,996 49.32 39.66 (11.82)  46.63 (11.08)  
Squamous Cell 973 16.02 38.03 (11.46) 0.003 45.69 (11.73) 0.305 
Large Cell 208 3.42 37.36 (11.33) 0.091 45.00 (11.30) 0.500 
Non-small cell 
carcinoma, non-specified 
972 16.00 37.40 (11.85) <0.001 45.20 (11.38) 0.009 
Small Cell 667 10.98 36.84 (11.67) <0.001 43.77 (11.62) <0.001 
Other 258 4.25 41.51 (11.92) 0.200 47.65 (11.37) 0.930 
Stage       
I 621 9.67 43.90 (11.46)  49.28 (10.39)  
II 228 3.55 43.68 (11.74) 1.000 50.09 (10.37) 0.988 
III 979 15.25 41.16 (11.79) <0.001 46.26 (11.21) <0.001 
IV 1,768 27.54 37.74 (11.82) <0.001 45.22 (11.52) <0.001 
Unknown 2,824 43.99 37.00 (11.30) <0.001 45.23 (11.34) <0.001 
P for trend      9.2x10-42   2.3x10-11 
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Figure 1. Distribution of PCS and MCS scores in the lung cancer study population  
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Table 2. Host Characteristics of Subset Population Analyzing the p38 MAPK Pathway  
Characteristics Discovery, N (%) Validation, N (%) P-Value 
MST 22.3 Months 20.4 Months  
Age, Mean(SD) 61.6 (10.9) 61.8 (11.0) 0.82 
Survival Time, Mean(SD) 28.3 (21.5) 27.7 (22.2) 0.71 
Sex    
Male 154 (48.0) 166 (51.9)  
Female 167 (52.0) 154 (48.1) 0.32 
Marital Status    
Married 239 (74.5) 243 (75.9)  
Widowed 36 (11.2) 32 (10.0)  
Separated 1 (0.3) 2 (0.6)  
Divorced 32 (10.0) 29 (9.1)  
Never Married 13 (4.1) 14 (4.4) 0.94 
Education     
<High School 30 (9.6) 28 (9.0)  
High School, Voc, AA 203 (64.9) 199 (64.2)  
College Degree  80 (25.6) 83 (26.8) 0.93 
Smoking Status    
Never 82 (25.6) 80 (25.1)  
Former 189 (59.1) 191 (59.9)  
Current 49 (15.3) 48 (15.1) 0.98 
Alcohol Use    
Never 146 (45.5) 136 (42.8)  
Former 38 (11.8) 42 (13.2)  
Current 137 (42.7) 140 (44.0) 0.75 
Previous Treatment       
Yes 28 (8.7) 23 (7.2)   
No 293 (91.3) 297 (92.8) 0.47 
Past Medical History    
Yes 281 (87.5) 268 (84.5)  
No 40 (12.5) 49 (15.5) 0.27 
Histology    
Adenocarcinoma 176 (57.3) 177 (57.5)  
Squamous Cell  52 (16.9) 51 (16.6)  
Other 79 (25.7) 80 (26.0) 0.99 
Stage    
I 62 (21.2) 52 (18.3)  
II 21 (7.2) 21 (7.4)  
IIIA 50 (17.1) 40 (14.0)  
IIIB 31 (10.6) 29 (10.2)  
IV 129 (44.0) 143 (50.2) 0.62 
Surgery    
No 218 (71.7) 220 (73.8)  
Yes 86 (28.3) 78 (26.2) 0.56 
Radiation    
No 235 (77.3) 222 (74.5)  
Yes 69 (22.7) 76 (25.5) 0.42 
Chemotherapy    
No 160 (52.6) 146 (49.0)  
Yes 144 (47.4) 152 (51.0) 0.37 
Chemotherapy/Radiation   
No 241 (79.3) 260 (87.3)  
Yes 63 (20.7) 38 (12.8) 0.009 
Performance Status    
0 75 (24.7) 84 (28.2)  
1 125 (41.1) 141 (47.3)  
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2-4 37 (12.2) 41 (13.8)  
Unknown 67 (22.0) 32 (10.7) 0.003 
PCS    
≥50 99 (30.8) 101 (31.6)  
<50 222 (69.2) 219 (68.4) 0.84 
MCS    
≥50 152 (47.4) 154 (48.1)  
<50 169 (52.7) 166 (51.9) 0.84 
Vital Status       
Alive 85 (26.5) 96 (30.0)   
Dead 236 (73.5) 224 (70.0) 0.32 
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2.3.2. Relationship between Demographic and Clinical Characteristics and PCS/MCS 
Scores 
Comparison of Mean PCS Scores 
      Table 1 shows the mean PCS score results. Patients who had a college degree (41.8, 
P<0.001) reported a statistically significantly higher mean PCS score when compared to 
individuals with less than a high school education (35.2). Interestingly, current drinkers had a 
higher mean PCS (41.9, P<0.001) score compared to never drinkers (37.2). The opposite effect 
was seen for current smokers, who showed a lower mean PCS (36.5, P<0.001) score when 
compared to never smokers (40.8). When examining racial differences, Blacks were more likely 
to have a low mean PCS (35.7, P<0.001) score compared to whites (38.9). The mean PCS 
score for widowed patients (37.0, P<0.001) was significantly lower compared to those currently 
married (39.2). The PCS scores for patients with squamous cell (38.0, P=0.003) and small cell 
(36.8, P<0.001) lung cancer were lower than those with adenocarcinoma (39.7). When 
stratifying by smoking (never or ever), patients who have ever smoked diagnosed with small 
cell lung (36.8, P<0.001) cancer reported worse PCS scores compared to those diagnosed with 
adenocarcinoma (39.2) (data not shown). Never smokers diagnosed with small cell lung cancer 
did not report significantly worse PCS scores compared to patients diagnosed with 
adenocarcinoma. Finally, stage III (41.2, P<0.001) and stage IV (37.7, P<0.001) lung cancer 
patients reported worse PCS scores compared to those with stage I (43.9).  
Poor PCS Risk 
      The results for the adjusted risk analysis are shown in Figure 2 and Appendix: 
Supplemental Table 1. Education was significantly associated with risk of reporting a poor 
PCS. When compared to less than a high school education patients with a college degree had 
a lower risk of reporting a low PCS (OR=0.50, 95% CI: 0.39-0.64, P=8.7x10-8). Smoking status 
was also significantly associated with PCS. When compared to never smokers, former smokers 
had a higher risk of reporting a poor PCS (OR=1.34, 95% CI: 1.11-1.61, P=0.002). Current 
smokers (compared to never smokers) had an even larger increased risk of reporting a poor 
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PCS (OR=1.81, 95% CI: 1.43-2.31, P=1.3x10-6). When examining clinical characteristics, 
squamous cell lung cancer patients were at a 41% increased risk of a poor PCS (OR =1.41, 
95% CI: 1.16-1.72, P=0.001). Individuals diagnosed with stage III (OR=1.45, 95% CI: 1.15-
1.84, P=0.002) and IV (OR=2.79, 95% CI: 2.23-3.50, P<1.0x10-63) lung cancer are at an 
increased risk of an unfavorable PCS score. Stage IV lung cancer patients showed the largest 
risk of a poor PCS of all determinants in the model. 
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Figure 2. Association between demographic/clinical Factors and PCS in lung cancer 
patients.  
Odds ratios adjusted by age, sex, race, marital status, education, smoking status, alcohol use, 
past medical treatment, past treatment, histology, and stage. 
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Comparison of Mean MCS Score 
      Results for the mean MCS score analysis are shown in Table 1. As participant’s age 
increased, their MCS score increased and the oldest age group reported a statistically 
significant higher mean MCS score (70+: 47.5, P<0.001) compared to the youngest age group 
(<50: 45.4), indicating their perception of their mental QOL was better than the youngest age 
group. MCS scores for patients who had a high school, vocational, or associates degrees 
(45.8, P<0.001) or a college degree (47.6, P<0.001) were higher compared to those who did 
not finish high school (42.6, Ptrend=7.1x10-24). Asian/Pacific Islanders (48.3, P=0.034) reported 
higher mean MCS scores compared to Whites (46.0). The lowest MCS score for alcohol usage 
was seen with former alcohol drinkers (44.5, P=0.033) and was significantly worse compared to 
never drinkers (45.5). Interestingly, current drinkers (47.1, P<0.001) reported a significantly 
higher MCS score compared to never drinkers. In addition, a downward trend of mean MCS 
scores was see for former (46.1, P<0.001) and current (43.6, P<0.001) smokers compared to 
never smokers (48.0, Ptrend=5.4x10-21). Divorced patients were more likely to have a worse 
mean MCS scores (44.1, P<0.001) compared to currently married patients (46.3). When 
examining histology type, patients with small cell lung cancer had the lowest MCS score (43.8, 
P<0.001) compared to those with adenocarcinoma (46.6). When stratifying by smoking, this 
relationship was only seen in ever smokers (data not shown). Finally, stage III (46.3, P<0.001) 
or IV (45.2, P<0.001) patients reported worse MCS scores compared to those with stage I 
(49.3) lung cancer.  
Poor MCS Risk 
      The results for the adjusted risk analysis are shown in Figure 3 and Appendix: 
Supplemental Table 2. Females were 41% (OR=1.41, 95% CI: 1.26-1.59, P=6.8x10-9) more 
likely to report a worse MCS when compared to males. Education was significantly associated 
with risk of reporting a poor MCS. Participants with a college degree had a lower risk of 
reporting a low MCS compared to patients with less than a high school education (OR=0.50, 
95% CI: 0.41-0.61, P=1.8x10-11). Asian/Pacific Islanders were more likely to report a better 
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MCS (OR=0.72, 95% CI: 0.54-0.98, P=0.035) compared to Whites. When compared to never 
smokers, former smokers had a higher risk of reporting a poor MCS (OR=1.40, 95% CI: 1.19-
1.65, P=3.8x10-5). Current smokers (when compared to never smokers) had an even bigger 
increased risk of reporting a poor MCS (OR=1.69, 95% CI: 1.38-2.06, P=2.9x10-7). Finally, 
patients diagnosed with stage IV lung cancer have a 75% (OR=1.76, 95% CI: 1.43-2.16, 
P=6.2x10-8) greater risk of reporting a worse MCS score compared to those diagnosed with 
stage I. As seen with PCS also, the stage IV lung cancer patients had the largest increased risk 
of poor MCS of all determinants examined in the model 
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Figure 3. Association between demographic/clinical factors and MCS in lung cancer 
patients 
Odds ratios adjusted by age, sex, race, marital status, education, smoking status, alcohol use, 
past medical treatment, past treatment, histology, and stage.  
 
* 
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2.3.3. Relationship between PCS/MCS Scores and Survival 
      Survival analysis results based on dichotomized PCS and MCS scores are presented in 
Table 3. Individuals with a PCS or MCS score less than 50, had an increased risk of death 
(PCS: HR=1.63, 95% CI: 1.51-1.77, P<1.0x10-63; MCS: HR=1.23, 95% CI: 1.16-1.32, P=7.2x10-
11). This increased risk resulted in a significant difference between median survival time (MST) 
of those with a PCS score less than 50 (MST=15.1 months) and those with a PCS score 
greater than 50 (MST=32.1 months, Plog-rank<0.0001) (Figure 4A). There was also a significant 
reduction in MST for patients with a MCS score less than 50 at only 15.4 months and those 
with a MCS greater than 50 at 21.7 months (Plog-rank<0.0001) (Figure 4B).  When stratifying by 
stage, the same effect is seen within the stage groupings (Figure 4C and 4D). 
 
 
 
Table 3. Association between Low PCS/MCS Score and Five-Year Overall Survival 
SF-12 Score Alive Dead 
Unadjusted HR 
(95% CI) P Value 
Adjusted HR 
(95% CI) P Value 
PCS       
High  645 852 1.00 (Ref)  1.00 (Ref)  
Low 1,344 3,579 1.91 (1.77-2.06) <1.0x10-63 1.63 (1.51-1.77) <1.0x10-63 
MCS       
High  956 1,787 1.00 (Ref)  1.00 (Ref)  
Low 1,033 2,644 1.34 (1.26-1.43) <1.0x10-63 1.23 (1.16-1.32) 7.2x10-63 
Abbreviations: HR=Hazard Ratio, CI-Confidence 
Interval    
*Adjusted for age, sex, race, smoking status, previous cancer treatment, treatment at MD 
Anderson, histology, and cancer stage 
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Figure 4. 5-year survival by quality of life measures in lung cancer patients and cancer 
stage; A) PCS scores B) MCS scores C) PCS Score by Stage D) MCS Score by Stage 
Scores were dichotomized at 50 representing the mean PCS/MCS score in the general 
population and stratified by cancer stage. 
 
 
 
 
 
 
 
 
A) B) 
D) C) 
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2.3.4. The Relationship between Genetic Variants in the p38 MAPK Pathway and 
PCS/MCS Scores 
Discovery Phase for PCS and MCS Scores 
      The association between genetic variants in the p38 MAPK pathway and PCS/MCS scores 
are shown in Appendix: Supplemental Table 3. Overall, 29 SNPs were associated with PCS 
score and 20 SNPS were associated with MCS score in the discovery analysis. The most 
significant genetic variant associated with PCS score was TNFRSF1B: rs496888, which was 
associated with a higher PCS score (OR=0.40, 95% CI: 0.21-0.75, P=0.004) under the 
dominant model. The most significant variant associated with MCS score was located in 
MAP2K3 (rs1466314) under the dominant model, with patients showing an over 2-fold 
increased risk of a poor MCS score (OR: 2.25, 95% CI: 1.31-3.87, P=0.003). 
Gene-base Analysis for PCS and MCS Scores  
      When analyzing the gene-based analysis results from the VEGAS software, many genes 
were significant contributors to PCS and MCS scores in the discovery phase (data not shown). 
For PCS score this included MAPK11 (P=0.011) and PEX7 (P=0.005). For MCS score, this 
included MAP2K3 (P=0.002) and TRAF2 (P=0.023). 
Validation Phase for PCS and MCS Scores 
      The validation phase results for MCS scores are seen in Table 4. No variants replicated 
when analyzing PCS score. One variant was replicated when analyzing variants and MCS 
score. In the discovery phase, individuals with homozygous variant genotype of MEF2B: 
rs2040562 showed a 3.06-fold increased risk of a poor mental health score (95% CI: 1.05-8.92, 
P=0.041), compared to subjects carrying at least one major allele. In the validation phase, 
individuals with homozygous variant genotype of MEF2B: rs2040562 showed a 2.61-fold 
increased risk of a poor MCS score (95% CI: 1.11-6.15, P=0.028) (when we combined 
discovery and validation phase: OR=2.43, 95% CI: 1.29-4.58, P=0.006 for rare homozygote 
genotype). When analyzing the gene-based analysis results, MAP2K6 was a significant 
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contributor to PCS score based on the discovery phase p-values (P=0.022) and the validation 
phase p-values (P=0.001) (data not shown).  
2.3.5. Relationship between Genetic Variants and Five-Year Survival 
      Appendix: Supplemental Table 4 provides the discovery phase of the association of 
genetic variants in the p38 MAPK pathway and five-year survival. Eighteen SNPs were 
significant. The most significant result was under the dominant model for MAP3K5: rs3765259. 
Patients with this variant had a decreased risk of dying (HR=0.56, 95% CI: 0.40-0.79, 
P=0.0008). Those with the common genotype had a MST of 17.3 months, those with one 
variant allele had a MST of 23.8 months (Plog-rank=0.053). No variants that were significant in the 
discovery phase replicated. 
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Table 4. Association Between p38 MAPK Validated Variant and MCS Score 
    Discovery Phase   
Gene: SNP Model 
MCS <50 
WW/WV/VV 
MCS≥50 
WW/WV/VV 
*OR (95% CI) P Value 
MEF2B: rs2040562 Rec. 86/60/23 75/70/7 3.06 (1.05-8.92) 0.041 
    
  
Validation Phase      
Gene: SNP Model 
MCS <50 
WW/WV/VV 
MCS≥50 
WW/WV/VV 
*OR (95% CI) P Value 
MEF2B: rs2040562 Rec. 62/76/28 56/84/14 2.61 (1.11-6.15) 0.028 
    
  
Combined Analysis 
    
Gene: SNP Model 
MCS <50 
WW/WV/VV 
MCS≥50 
WW/WV/VV 
*OR (95% CI) P Value 
MEF2B: rs2040562 Rec. 148/136/51 131/154/21 2.43 (1.29-4.58) 0.006 
Abbreviations: OR-Odds Ratio, Rec.-Recessive 
*Adjusted for age, sex, marital status, education, smoking, alcohol, past medical 
treatment, previous treatment, histology, and stage  
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2.4. Discussion 
      To date there have been no studies reported that examine the association of detailed 
demographic and clinical characteristics and QOL in lung cancer patients. Furthermore, no 
study to data has examined the association of p38 MAPK genetic variants and QOL and 
survival. The results of this comprehensive study characterize the baseline demographic, 
epidemiological, clinical and genetic determinants of QOL in a large population of recently 
diagnosed lung cancer patients. Alcohol use, smoking, education, and higher lung cancer stage 
were consistently shown to impact mean PCS and MCS. Poor PCS and MCS QOL scores 
were associated with increased risk of death. Genetic variants in the p38 MAPK pathway were 
associated with PCS/MCS scoring. A validated SNP (MEF2B: rs2040562) was associated with 
an increased risk of poor MCS score. 
      The link between smoking and risk of lung cancer is well established. For our study, there 
were 1,197 current and 4,083 former smokers. Previous research has found that the majority of 
smokers who are current smokers when diagnosed with lung cancer will continue to smoke 
regardless of their cancer diagnosis(140). In our study, former and current smokers reported 
worse PCS and MCS scores compared to never smokers, and poor QOL in current smokers is 
consistent with the literature(128, 129). For example, one study that examined QOL and 
smoking status in SCLC patients with a positive smoking history found that patients that quit a 
year or more before their diagnosis reported better QOL scores compared to patients that quit 
within one year of their diagnosis or were still smoking at the time of their diagnosis(128). This 
is in line with our results in that current smokers reported lower PCS and MCS QOL scores 
than former smokers. Another study that grouped patients based on how their smoking status 
changed from diagnosis to one-year post diagnosis found that never smokers reported the best 
QOL, followed by former smokers, abstinent smokers (patients who quit between lung cancer 
diagnosis and one-year follow-up), and persistent smokers (patients who smoked at diagnosis 
and continued to smoke one-year follow-up)(129). In our study, former smokers reported 
slightly higher PCS and MCS scores than current smokers. This suggests that even 
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participants who are former smokers do not feel that their QOL is as high as never smokers, 
but does suggest that quitting smoking may lead to improved QOL. This presents the possibility 
of future smoking cessation programs in lung cancer survivors to assist current smokers in 
becoming former smokers with the goal of increasing their QOL and thus, potentially improving 
long-term prognosis. 
      Current alcohol users reported higher mean PCS and MCS scores than never drinkers and 
former drinkers. A previous study examining health perceptions in lung cancer survivors (5 to 
21 years post diagnosis) found that approximately 69% of participants retrospectively self-
reported that they were current drinkers when they were diagnosed with lung cancer and 57% 
of participants were still currently drinking(141). Those that were currently drinking were at a 
higher risk of reporting worse perception of health status(141). Interestingly, we found the 
opposite finding in our analysis for physical QOL in recently diagnosed lung cancer cases. Our 
analysis is the first to our knowledge that has examined alcohol use and QOL in newly 
diagnosed lung cancer cases. Further analysis is warranted to dissect the potentially 
complicated relationship between alcohol use and QOL.     
      Previous research has shown that healthy individuals with lower education levels report 
worse QOL and therefore are diagnosed with chronic diseases more frequently compared to 
those with more favorable QOL(142-144). There is limited research on the association between 
education level and QOL in lung cancer patients. The few studies on lung cancer found that 
lower education level is associated with poorer performance status in clinical trial 
participants(145, 146) and higher education is associated with better QOL and lower symptom 
levels(147). Mixed results have been seen between education level and different aspects of 
QOL in NSCLC patients (148) and survivors (149). Specifically, lower educated survivors of 
NSCLC (treated by surgery) displayed better cognitive functioning compared to individuals with 
a higher education level but they also reported worse pain and financial related stress(149). 
Cognitive functioning, pain, stress, and symptoms are variables that affect QOL. Our study is 
first to examine education level and QOL in a large population of newly diagnosed patients and 
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we showed that patients with at high school degree or higher were more likely to report higher 
PCS and MCS scores. Further research is needed to determine possible disparities feeding 
into the gap between QOL and education level in patients.  
      The p38 MAPK pathway has been associated with QOL and QOL factors such as 
depression, pain, and there is evidence of an association with anxiety in animal models(112, 
150, 151). Individuals diagnosed with major depression have increased levels of 
proinflammatory cytokines and corresponding receptors in peripheral blood and cerebral spinal 
fluid(112, 152), and proinflammatory cytokines activate the p38 MAPK pathway, which 
subsequently and can activate the serotonin transporter (SERT)(153). Furthermore, research 
has linked the activation of the p38 MAPK pathway to regulation of mood-related 
neurotransmitters, with potential links to the regulation of synaptic plasticity(154). Our study 
discovered multiple variants in p38 MAPK pathway genes that were associated with PCS and 
MCS scores. One variant (MEF2B: rs2040562) was replicated in association with mental QOL. 
Myocyte-enhancing factor 2B (MEF2B) protein is a transcription factor that is important in 
development and adulthood and is important in regulating transcriptional programming(155). 
The variant rs2040562, that validated, is intronic. Research has shown that patients with 
metastatic renal cell carcinoma who are depressed (compared to non-depressed patients) 
show increased expression of MEF2(156). Our results suggest that individuals with a variant in 
MEF2B are at an increased risk of reporting a poor MCS score. Therefore, further research 
needs to be completed to untangle the mechanism behind this relationship. 
      Finally, we identified that individuals with poor reported PCS or MCS scores are at a higher 
risk for death within five-years of diagnosis and our results support and extend previous 
findings(157-161) that examined QOL during or following treatment. We examined QOL at 
baseline and studies that examined baseline QOL and survival in lung cancer patients support 
our findings(25, 118, 120, 121, 123, 162-165). Our findings remained true after controlling for 
stage and treatment. Previous studies have shown this relationship in patients with Stage I 
NSCLC that received pulmonary resection(161), further providing evidence that QOL is an 
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important prognostic indicator even in early stage patients. Our patient population was unique 
in that it was heterogeneous in terms of consisting of multiple types of lung cancer. The 
majority of studies examining QOL and survival in lung cancer patients focus on NSCLC. For 
example, one study examining 1,194 NSCLC patients found that overall QOL and physical 
functioning were independently associated with survival in a multivariate analysis controlling for 
stage and other confounders(123). One study did examine baseline QOL and survival in a 
small sample of mixed histology’s. They found that pre-diagnosis QOL (in patients suspected to 
have lung cancer) was associated with survival. Specifically, those that reported better QOL 
were less likely to die(118). These results further highlight that many factors influence survival 
and stress the importance of potential behavioral interventions in the clinical setting to increase 
QOL and potentially improve survival.  
      Because of the significant association between QOL and survival that has been shown in 
many studies, an effort should be made to implement this in the clinic. According to 
researchers, a barrier to clinical use isn’t the lack of valid measures of QOL, it is the difficult 
nature of implementing QOL into busy clinic schedules(165, 166). In contrast, because QOL is 
becoming a recognized aspect of cancer care, QOL has become an important endpoint of 
clinical trials(166). 
      The strengths of this study include a large study population and the ability to assess the 
relationship of various demographic, epidemiological, clinical, and genetic factors with QOL. 
The results of this study are important in that they provide an overarching picture of key QOL 
factors that affect lung cancer patients. This information could be used to identify potential 
interventions to improve QOL, as well as those at increased risk of a poor treatment response 
and prognosis due to their reduced QOL.  The main limitation of this study is that over 2,800 
patients were missing stage information. The results of a sensitivity analysis showed 
consistency between the full model and the reduced model.   
      In conclusion, we have identified several determinants that contribute to and mediate QOL 
in lung cancer patients. The results of this study can be used to identify patients that may have 
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a worse QOL and are at risk for a poor prognosis. This could result in more of a proactive 
approach in the clinic to treating the patient as a whole, identifying genetically susceptible 
patients, and addressing health behaviors that impact QOL, such as smoking cessation as a 
step to improve patient well-being and overall survival.   
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Chapter 3. Quality of Life, its Socio-Demographic and Racial 
Determinants, and Clinical Outcomes among Breast Cancer Patients 
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3.1. Introduction 
      Breast cancer is the number one diagnosed cancer and the number two cause of cancer 
related death in women in U.S.(1). Breast cancer is a heterogeneous disease and is often 
classified in three receptor subtypes: Hormone-receptor positive (HmR-positive), human 
epidermal growth factor 2 positive (HER2-positive), and triple-negative(58, 167). The receptor 
subtypes of breast cancer are important in regards to optimal treatment options and prognosis 
of disease(168). Triple-negative breast cancer is the most aggressive of the three major 
subtypes and is found in higher rates in Black women and younger pre-menopausal 
women(140, 169). 
      QOL is a multidimensional concept that spans the psychological, physical, financial, and 
spiritual aspects of a person’s life(170). QOL has become an important part of a cancer 
patient’s treatment plan due to the association of better survival in patients with better QOL, 
including breast cancer patients(119, 171). Breast cancer patients can have many different 
QOL concerns to deal with. Physical QOL issues such as fatigue, pain, nausea are common in 
women with breast cancer(170). Research supports that there are racial disparities when 
measuring QOL in breast cancer patients. For example, Hispanic women have been shown to 
report worse mental, physical, and social QOL compared to other race groups(172). African 
Americans report low QOL in some domains and high QOL in other domains. In one study, 
African Americans reported lower functional well-being and higher emotional well-being 
compared to White women(96). Many studies that examined racial disparities of QOL in breast 
cancer patients focused on these issues in long-term breast cancer survivors(173-176) but not 
on recently diagnosed patients. Furthermore, the studies that did examine QOL at diagnosis 
are plagued by small sample sizes. Currently, there lacks a comprehensive study that 
examines predictors of QOL at diagnosis and how predictors vary across racial groups.  
      Racial disparities exist for survival time for many types of cancer(60). When examining 
racial disparities in breast cancer specifically, Black women actually have slightly lower 
incidence rates of breast cancer compared to White women(60). While Black women have a 
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lower incidence of breast cancer, they are typically diagnosed with later stage disease, are at a 
higher risk for recurrence, and have the worst survival(60, 177, 178). Black women also have 
the worst survival for each known stage of disease at diagnosis(30, 60) while Asian/PI patients 
have the highest survival(60). Some reasons for the disparity in Black women are known. For 
example, lack of access to care and inferior treatment are all considered important 
factors(179), but that is thought to only contribute partially to the disparity in mortality. Another 
potential reason for the disparity in survival is due to the fact that African Americans are more 
likely to be diagnosed with more aggressive molecular subtypes like triple-negative which have 
poorer outcomes(41). In addition, Hispanics also show worse survival compared to Whites and 
this may be due to receiving inferior care(180). Another potential factor that could contribute to 
racial disparities in survival of breast cancer is health-related QOL(181).  
      In this current study, we aim to establish the association between QOL and clinical 
outcomes using a large population from The University of Texas MD Anderson Cancer Center. 
We also aim to discover the host and clinical predictors of QOL in newly diagnosed breast 
cancer patients, and how these determinants vary in distribution across race groups, with the 
ultimate goal being to characterize host and clinical characteristics among racial groups.  
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3.2. Methods 
3.2.1. Patient Population 
      Patients for this study were obtained from The University of Texas MD Anderson Cancer 
Center from 2002 to 2011. There were 10,681 women newly diagnosed with Stage I through III 
breast cancer that were diagnosed within one year of enrollment. Patients completed an 
institutional intake questionnaire within one year of their diagnosis. All patients completed 
written informed consent and this study was approved by The University of Texas MD 
Anderson Cancer Center Institutional Review Board. 
3.2.2. Data Collection 
Epidemiologic Data 
      The institutional intake questionnaire asked epidemiologic questions. These included 
questions regarding self-reported race, age, smoking history, alcohol history, past medical 
history, marital status, and education level. Race/Ethnicity was classified as “White”, “Hispanic”, 
“Black”, “Asian/PI”, “Other”. Alcohol consumption and smoking status was classified into three 
groups: “Never”, “Former”, and “Current”. Patients were classified as a “current” drinker if they 
drank at least one drink per month. BMI was measured at time of first clinic appointment. 
Patients were asked to self-report if they had ever had any of the following past medical history 
events: Diabetes, stroke, heart or lung problems, high blood pressure, bleeding problems, liver 
problems, thyroid problems, frequent infections, kidney problems, HIV/AIDS, psychiatric or 
psychological issues, seizures, or circulation issues. Clinical data was abstracted from 
electronic medical records by trained staff. Pathology data, survival data, and treatment 
information was obtained from MD Anderson’s Tumor Registry. 
Quality of Life 
      A QOL questionnaire (SF-12v1) was included in the institutional intake questionnaire that 
patients completed. The SF-12v1 is a validated QOL measure(89) that measures patient’s 
physical and mental QOL by calculating a physical component summary score (PCS) and 
mental component summary score (MCS)(89). The 12 questions in the questionnaire referred 
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to the previous four weeks. Eight subscales (physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional, and mental health) were calculated 
from the responses which are used to formulate the PCS and MCS. The PCS and MCS score 
were normalized to a mean of 50 (SD=10) based on the US general population. A higher score 
indicates a better QOL. The pain question in the SF-12v1 that asked “During the past 4 weeks, 
how much did pain interfere with your normal work” was modified and scoring was adjusted to 
match the SF-12v1 scoring in our patient intake questionnaire as “During the past week, has 
pain interfered with your general activities”.  
3.2.3. Statistical Analysis 
      To analyze the association between QOL and overall survival and recurrence in breast 
cancer patients, Cox proportional hazard regression was used to calculate hazard ratios (HRs), 
95% confidence intervals (95% CI), and p-values. Patients that died or who were alive at last 
follow-up without recurrence were censored. Recurrence was either local, regional, or distant 
metastatic recurrence and time to recurrence was defined from the date of diagnosis to the 
date of first recurrence, date of last follow-up, or date of death, whichever came first. Survival 
time was calculated from date of diagnosis to the date of death or the date of last follow-up, 
whichever came first. PCS and MCS were grouped into five score groups starting at 40 and 
increasing by half standard deviation (a score increase of 5), to understand how survival and 
recurrence may differ as PCS and MCS score changes. The recurrence model was adjusted 
for age, race, diagnosis year, cancer detection method, nuclear grade, histology, tumor size, 
number of positive lymph nodes, lymphatic/vascular invasion, adjuvant hormone therapy, 
alcohol use, receptor subtype, and stage. Survival model was adjusted for age, race, cancer 
detection method, nuclear grade, tumor size, number of positive lymph nodes, 
lymphatic/vascular invasion, chemotherapy, adjuvant hormone therapy, receptor subtype, 
smoking, and stage. These factors were based on a previous prognostic model study that 
investigated a comprehensive list of potential predictors including receptor subtypes, 
epidemiological data, QOL, and treatment data and these factors were found to be significant 
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predictors(58). Kaplan-Meier curves were generated to assess the survival and recurrence 
differences among races and among PCS and MCS scores. Log-rank tests were performed to 
assess differences in survival and recurrence by race and QOL score. A subset of the study 
population had detailed clinical data. To test for differences in mean PCS and MCS scores 
among host and clinical characteristics, an ANOVA test was used and SIDAK was used to 
correct multiple comparisons. Adjusted linear regression was completed for clinical factors 
using the clinical subset population to provide adjusted p values for multiple comparison testing 
(adjusting for age, race, education, BMI, marital status, smoking, alcohol use, past medical 
history score, stage, previous treatment, cancer detection method, nuclear grade, 
lymphatic/vascular invasion, tumors size, number of positive lymph nodes, breast cancer 
receptor status, histology, year diagnosed, and menopause status). 
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3.3. Results 
3.3.1. Host Characteristics 
      Table 5 shows the host characteristics of the study population. The majority of patients 
were between the ages of 45 and 54 years. Approximately 70% of the study population was 
White, followed by similar numbers of Hispanics and Blacks and only 4.9% of the population 
was Asian/PI. Over 4,500 (46.7%) women had at least a college degree and over 6,500 
(65.1%) women were never smokers. Of the three BMI categories, 36.8% of women fell in to 
the normal/underweight BMI category (BMI<25). For a subset of the study population we had 
extensive clinical data (N=6,807). When examining clinical characteristics, most women in this 
study were diagnosed with HmR-positive receptor subtype (N=4,434), and 3,231 women 
detected their cancer by screening and 3,526 women detected their cancer by symptoms. 
Distributions of epidemiologic factors were similar between the full population and the subset of 
clinical population (Table 6) indicating the two populations were similar. 
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Table 5. Study Host and Clinical Characteristics    
Epidemiology Characteristics N % Clinical Characteristics* N % 
Age   Breast Cancer Receptor Subtype   
18-44 2,620 25.7 HmR-Positive 4,434 69.6 
45-54 3,399 33.3 HER2-Positive 995 15.6 
55-64 2,571 25.2 Triple-Negative 943 14.8 
≥65 1,607 15.8 Adjuvant  Hormone Therapy   
Race   Yes 4,447 65.3 
White 7,002 70.5 No 2,360 34.7 
Hispanic  1,186 11.9 Chemotherapy   
Black 1,021 10.3 Yes 4,390 64.5 
Asian/PI 490 4.9 No 2,417 35.5 
Other 237 2.4 Cancer Detection Mode   
Education Level   Screening 3,231 47.8 
High School or Less 2,516 25.8 Symptoms 3,526 52.2 
AA/Voc 2,685 27.5 Nuclear Grade   
College Degree  or Greater 4,548 46.7 I or II 3,464 51.9 
Marital Status   III 3,210 48.1 
Married 7,210 70.8 Lymphatic or Vascular Invasion   
Never Married 1,214 11.9 No 5,097 75.1 
Other 1,765 17.3 Yes 1,686 24.9 
Smoking   Tumor Size   
Never 6,566 65.1 0-1 cm 1,849 28.8 
Former 2,708 26.8 1-2 cm 2,336 36.3 
Current 820 8.1 ≥3 2,247 34.9 
Alcohol   Diagnosis Year   
Never 4,897 48.6 1999-2002 722 10.6 
Former 757 7.5 2003-2007 2,593 38.1 
Current 4,418 43.9 2008-2012 3,492 51.3 
BMI   Menopause   
<25 2,412 36.8 Premenopause 4,017 59.1 
25-29.9 1,962 30.0 Perimenopause 2,586 38.1 
≥30 2,175 33.2 Postmenopause 191 2.8 
Past Medical History Score   Positive Lymph Nodes   
0 2,952 29.0 0 3,737 55.5 
1 3,063 30.0 1 or 2 1,587 23.6 
2 2,180 21.4 ≥3 1,413 21.0 
≥3 2,002 19.6 Histology   
Previous Treatment   Ductal 5,421 79.6 
Yes 4,321 42.4 Lobular 584 8.6 
`No 5,876 57.6 Mixed Ductal/Lobular 402 5.9 
Stage   Other 400 5.9 
I 1,517 14.9    
II 2,071 20.3    
III 890 8.7    
Unknown 5,719 56.1    
*Clinical data only available for a subset (N=6,807) of patients    
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Table 6. Distribution of Host Characteristics in Subset Population 
Epidemiology Factors N % 
Age   
18-44 1,705 25.1 
45-54 2,204 32.4 
55-64 1,768 26.0 
≥65 1,130 16.6 
Race   
White 4,663 70.4 
Hispanic  820 12.4 
Black 665 10.0 
Asian/PI 323 4.9 
Other 154 2.3 
Education Level   
High School or Less 1,766 27.1 
AA/Voc 1,775 27.3 
College Degree  or Greater 2,967 45.6 
Marital Status   
Married 4,784 70.3 
Never Married 798 11.7 
Other 1,219 17.9 
Smoking   
Never 4,338 64.4 
Former 1,847 27.4 
Current 549 8.2 
Alcohol   
Never 3,255 48.4 
Former 505 7.5 
Current 2,961 44.1 
BMI   
<25 2,412 36.8 
25-29.9 1,962 30.0 
≥30 2,175 33.2 
Previous Treatment   
No 4,070 59.8 
Yes 2,737 40.2 
Past Medical History Score   
0 1,948 28.6 
1 2,039 30.0 
2 1,473 21.6 
≥3 1,347 19.8 
Stage   
I 1,403 37.6 
II 1,682 45.0 
III 650 17.4 
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3.3.2. Predictors of Clinical Outcomes in Breast Cancer Patients 
QOL and Overall Survival 
      The results showing the association between PCS/MCS and overall survival are shown in 
Table 7. Compared to patients with a PCS of 55 or greater, as PCS decreased by half a 
standard deviation (5 points), there was a dose-dependent increase in the risk of death with 
patients who reported a PCS score of less than 40 having the highest risk of death (HR=2.00, 
95% CI: 1.64-2.43, P=3.5x10-12). Figure 5A shows the Kaplan-Meier curves assessing the 
difference in survival by PCS score (PLog-rank<0.0001). Patients with a PCS of less than 40 
showed the worst survival, with a median survival time (MST) of 11.7 years, followed by 
patients with a PCS score of 40 through 44 (MST=12.5 years). When examining mental QOL 
and risk of death, there was no significant association between MCS score and risk of death in 
the adjusted regression model. Figure 5C shows the Kaplan-Meier curve of MCS score and 
survival (PLog-rank=0.005). We also analyzed PCS score and overall survival by stage (I-III). The 
trends were similar to the overall results (Figure 6A and Figure 6B). 
QOL and Risk of Recurrence 
      Table 7 shows the results of the association between PCS/MCS and recurrence. Patients 
who scored 40-44 or <40 on the PCS had a significant 41% (HR=1.41, 95% CI: 1.05-1.91, 
P=0.023) or 42% (HR=1.42, 95% CI: 1.12-1.80, P=0.003) increase in the risk of recurrence, 
respectively. The difference in recurrence by PCS score is seen in Figure 5D. Patients with a 
PCS score of less than 40 showed the highest recurrence compared to the other PCS groups 
(PLog-rank<0.0001). For MCS score, there was no significant association with recurrence (Table 
7). The results were stratified by stage and trends were similar to the overall results (Figure 6C 
and Figure 6D). 
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Table 7.  The Association Between PCS/MCS and Survival and Recurrence 
Score Event  No Event HR (95% CI)* P Value 
Survival     
PCS Score     
PCS>=55 (Ref) 208 2,161 1.00 (Ref)  
PCS 50-54 167 1,294 1.23 (1.00-1.51) 0.054 
PCS 45-49 103 631 1.40 (1.10-1.78) 0.006 
PCS 40-44 87 469 1.59 (1.23-2.05) 4.6x10-4 
PCS<40 266 932 2.00 (1.64-2.43) 3.5x10-12 
Dichotomized PCS Score     
≥50 375 3,455 1.00 (Ref)  
<50 456 2,032 1.58 (1.36-1.82) 6.0x10-10 
MCS Score     
MCS>=55 (Ref) 242 1,765 1.00 (Ref)  
MCS 50-54 148 1,045 1.05 (0.85-1.29) 0.664 
MCS 45-49 105 848 0.95 (0.76-1.20) 0.687 
MCS 40-44 114 601 1.16 (0.92-1.46) 0.210 
MCS<40 222 1,228 1.07 (0.88-1.29) 0.510 
Dichotomized MCS Score     
≥50 400 2,901 1.00 (Ref)  
<50 431 2,586 1.01 (0.87-1.16) 0.937 
Recurrence     
PCS Score     
PCS≥55 (Ref) 205 2,325 1.00 (Ref)  
PCS 50-54 151 1,401 1.19 (0.94-1.50) 0.141 
PCS 45-49 80 710 1.14 (0.85-1.51) 0.381 
PCS 40-44 80 522 1.49 (1.10-2.00) 0.009 
PCS<40 201 1,073 1.45 (1.14-1.83) 0.002 
Dichotomized PCS Score     
≥50 356 3,726 1.00 (Ref)  
<50 361 2,305 1.26 (1.06-1.49) 0.009 
MCS Score     
MCS≥55 (Ref) 203 1,940 1.00 (Ref)  
MCS 50-54 128 1,139 0.99 (0.77-1.26) 0.915 
MCS 45-49 93 922 0.81 (0.62-1.07) 0.141 
MCS 40-44 99 672 1.14 (0.87-1.49) 0.343 
MCS<40 194 1,358 0.91 (0.73-1.14) 0.422 
Dichotomized MCS Score     
≥50 344 3,174 1.00 (Ref)  
<50 373 2,857 0.92 (0.78-1.08) 0.295 
*Adjusted for host and clinical factors 
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Figure 5. The Association between quality of life measures and clinical outcomes in the 
breast cancer study population; A) PCS and survival B) PCS dichotomized by 50 and 
survival C) MCS and survival D) MCS dichotomized by 50 and survival E) PCS and 
Recurrence F) PCS dichotomized by 50 and recurrence G) MCS and recurrence H) MCS 
dichotomized by 50 and recurrence 
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Figure 6. The Association between quality of life measures and clinical outcomes in the 
breast cancer study population by stage; A) PCS and survival B) MCS and Survival C) 
PCS and recurrence D) MCS and recurrence 
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3.3.3. Differences in Clinical Outcomes by Race 
      Figure 6A shows the Kaplan Meier curve for overall survival differences by race. Asian/PI 
patients showed the best survival compared to the other race groups. Black patients showed 
the worst survival compared to all other racial groups (PLog-rank<0.0001). Figure 6B showed the 
difference in recurrence between racial groups. Black patients showed the highest recurrence 
compared to other racial groups (PLog-rank<0.0001). 
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Figure 7. The association between race and clinical outcomes in breast cancer patients; 
A) Race and overall survival B) Race and recurrence 
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3.3.4. QOL Distribution by Race 
PCS 
      Next, the distribution of PCS score was analyzed by race (Figure 7A). Asian/PI showed the 
highest percentage of patients with a PCS score of greater than or equal to 50 (64%), 
indicating a good QOL. Asian/PI also had the lowest percentage (32%) of patients who 
reported a PCS of less than 30 (two standard deviations below the US mean of 50). In contrast, 
Black patients had the highest percentage of patients that reported a PCS of less than 30 
(12%), and the lowest percentage of patients that reported a PCS of 50 or greater (50%). 
Hispanics had the next lowest percentage of patients who reported a PCS of 50 or greater 
(58%). 
MCS 
      When analyzing the distribution of MCS score by race (Figure 7B), Black breast cancer 
patients had the highest percentage (54%) of participants who scored 50 or greater, indicating 
a good QOL. Hispanic patients had the highest proportion (9%) of patients who had a MCS 
score of less than 30, with Asian/PI, White, and Black groups all having 7% of patients who 
scored less than 30. Hispanics also had the lowest percentage of patients that scored a MCS 
score of 50 or greater, meaning they had the lowest proportion of patients with good mental 
QOL. 
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Figure 8. Distribution of quality of life measures among Race; A) Distribution of PCS B) 
Distribution of MCS 
Grouped by Scores of <30, 30-50, and ≥50. 
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3.3.5. Determinants of QOL 
PCS 
      Table 8 shows the results of how PCS score differs among different host and clinical 
factors. For the host characteristics, BMI was inversely associated with PCS with patients who 
had a BMI of 30 or greater (PCS=46.5) reporting a 5 point lower PCS score compared to 
patients with a BMI of <25 (PCS=51.6, P=1.1x10-20). Hispanic and Black patients were more 
likely to report lower PCS scores (PCS=47.9 P=0.005, PCS=46.4 P=0.008, respectively) 
compared to White patients (PCS=49.4). College educated or post graduate educated patients 
reported higher PCS scores (PCS=50.7) compared to patients with a high school education or 
less (P=46.9, P=1.6x10-6). When examining clinical characteristics, breast cancer patients who 
discovered their cancer by regular screening methods reported higher PCS scores (PCS=49.4) 
than patients who discovered their cancer based on symptoms (PCS=48.8, P=6.7x10-4). Triple-
negative patients reported on average a 2 point lower PCS score (PCS=47.5, P<0.001) 
compared to patients with HmR-positive cancer (PCS=49.4), which was not significant in the 
adjusted analysis. Perimenopausal women reported higher PCS (PCS=50.7, P=0.042) scores 
compared to premenopausal women (PCS=48.0).  
      
 
 
 
 
 
 
 
 
 
 
64 
 
Table 8.  Demographic and Clinical Predictors of PCS     
Characteristic N 
Mean PCS 
(SD) P Value P Value* 
Clinical 
Characteristic N  
Mean PCS 
(SD) P Value P Value*  
Age       
 Cancer 
Detection 
Method        
18-44 2,260 50.2 (9.5)   Screening 3,231 49.4 (9.7)   
45-54 3,399 49.6 (9.8) 0.211 0.829 Symptoms 3,526 48.8 (10.1) 0.047 6.7x10-4 
55-64 2,571 48.2 (10.6) <0.001 0.704 Nuclear Grade     
≥65 1,607 46.4 (10.7) <0.001 0.020 I or II 3,464 49.7 (9.6)   
Ptrend   <0.001  III 3,210 48.5 (10.2) <0.001 0.489 
BMI    
 Lymphatic or 
Vascular 
Invasion     
<25 2412 51.6 (8.9)   No 5,097 49.4 (9.8)   
25-29 1962 49.4 (9.7) <0.001 5.6x10-5 Yes 1,686 48.3 (10.4) <0.001 0.136 
≥30 2175 46.5 (10.4) <0.001 1.1x10-20 Tumor Size     
Race     0-1 cm 1,849 50.2 (9.5)   
White 7,002 49.4 (10.0)   1-2 cm 2,336 49.4 (9.7) 0.088 0.095 
Hispanic 1.186 47.9 (10.6) <0.001 0.005 >=3 2,247 47.8  (10.4) <0.001 2.7x10-6 
Black 1,021 46.4 (10.8) <0.001 0.008 
Number of 
Positive 
Lymph Nodes     
Asian/PI 490 50.0 (8.8) 0.938 0.084 0 3,737 49.8 (9.5)   
Other 237 48.3 (10.5) 0.806 0.391 1 or 2 1,587 49.1 (10.1) 0.109 0.013 
Education     >=3 1,413 47.5 (10.6) <0.001 6.7x10
-4 
HS or Less 2,516 46.9 (10.8)  
 Receptor 
Subtype     
Voc./AA 2,685 48.0 (10.5) 0.001 0.715 HmR-positive 4,434 49.4 (9.8)   
College  4,548 50.7 (9.3) <0.001 1.6x10-6 HER2-positive 995 49.2 (10.0) 0.910 0.672 
Alcohol     Triple-negative 943 47.5 (10.6) <0.001 0.101 
Never 4,897 47.5 (10.7)   Menopause     
Former 757 45.8 (11.1) <0.001 0.021 Premenopause 4,017 48.0 (10.3)   
Current 4,418 51.0 (8.9) <0.001 5.4x10-12 Perimenopause 2,586 50.7 (9.2) <0.001 0.042 
Smoking      Postmenpause 191 49.9 (10.1) 0.062 0.970 
Never 6,566 49.3 (9.9)  
 Diagnosis 
Year     
Former 2,708 48.6 (10.3) 0.044 0.241 1999-2002 722 49.1 (10.3)   
Current 820 46.9 (11.1) <0.001 1.9x10-6 2003-2007 2,593 49.2 (9.8) 0.976 0.633 
Marital Status     2008-2012 3,492 49.0 (9.9) 0.994 0.677 
Married 7,210 49.5 (9.8)   Histology     
Never Married 1,214 47.9 (10.7) <0.001 1.9x10-4 Ductal 5,421 49.0 (10.0)   
Other 1,765 46.9 (11.0) <0.001 0.038 Lobular 584 50.0 (9.3) 0.136 0.111 
Past Medical 
History Score    
 Mixed 
Ductal/Lobular 402 49.4 (10.0) 0.970 0.900 
0 2,952 51.4 (8.5)   Other 400 48.4 (10.3) 0.719 0.753 
1 3,063 50.1 (9.3) <0.001 9.3x10-4      
2 2,180 48.5 (10.2) <0.001 1.4x10-10      
≥3 2,002 43.8 (11.7) <0.001 9.3x10-63      
Previous 
Treatment    
 
    
None 5,876 50.9 (9.2)       
Yes 4,321 46.1 (10.8) <0.001 9.0x10-20     
Stage         
I 1,517 51.3 (9.0)       
II 2,071 51.2 (9.1) 1.000 6.8x10-5     
III 890 49.7 (9.9) 0.001 0.096     
*Adjusted 
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MCS  
      Table 9 shows the host and clinical characteristics analyzed to assess the difference in 
MCS scores among groups to better understand predictors of mental QOL. Patients who were 
55 years of age and older (Age 55-64: MCS=48.6, P=2.7x10-10; Age≥65: MCS=50.8, P=1.2x10-
23) reported significantly higher MCS scores compared to patients who were between the ages 
of 18 and 44 (MCS=46.2). Blacks showed a higher MCS score (MCS=48.4, P=5.8x10-5) 
compared to White patients (MCS=47.8). College educated/post graduate school (MCS=48.4, 
P=1.1x10-5) patients were more likely to report a higher MCS compared to patients who had a 
high school degree or less (MCS=47.3). Former (MCS=47.4, P=0.002) and current (MCS=43.7, 
P=6.4x10-11) smokers and former alcohol drinkers (MCS=45.3, P=3.9x10-6) reported, on 
average, lower MCS scores compared to never smokers (MCS=48.4) and never drinkers 
(MCS=48.2), respectively. When examining clinical characteristics and how MCS scores differ 
among groups, women who discovered their breast cancer based on symptoms scored lower 
mean MCS scores (MCS=46.9, P=0.001) compared to women who discovered their cancer by 
routine screening (MCS=48.6). Patients with a nuclear grade III tumor (MCS=47.1, P<0.001) 
and patients with lymphatic vascular invasion (MCS=47.0, P=0.005) reported lower MCS 
scores compared to patients with grade I or II tumors (MCS=48.3) or tumors with no lymphatic 
vascular invasion (MCS=48.0), but these associations were not significant in the adjusted 
analysis.  
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Table 9. Host and Clinical Predictors of MCS 
 
   
Characteristic N  
Mean 
MCS (SD) P Value P Value* 
Clinical 
Characteristic N  
Mean   
MCS (SD) P Value P Value*  
Age       
 Cancer 
Detection 
Method        
18-44 2,260 46.2 (10.5)   Screening 3,231 48.6 (10.2)   
45-54 3,399 46.9 (10.4) 0.129 0.033 Symptoms 3,526 46.9 (10.7) <0.001 0.001 
55-64 2,571 48.6 (10.3) <0.001 2.7x10-10 Nuclear Grade     
≥65 1,607 50.8 (9.6) <0.001 1.2x10-23 I or II 3,464 48.3 (10.3)   
Ptrend   <0.001  III 3,210 47.1 (10.6) <0.001 0.870 
BMI    
 Lymphatic or 
Vascular 
Invasion     
<25 2,412 47.7 (10.4)   No 5,097 48.0 (10.4)   
25-29 1,962 48.1 (10.3) 0.555 0.235 Yes 1,686 47.0 (10.5) 0.005 0.614 
>=30 2,175 47.3 (10.6) 0.307 0.643 Tumor Size     
Race     0-1 cm 1,849 48.5 (10.1)   
White 7,002 47.8 (10.3)   1-2 cm 2,336 47.8 (10.4) 0.179 0.219 
Hispanic 1,186 46.9 (10.8) 0.055 0.533 >=3 2,247 47.3 (10.7) 0.002 0.295 
Black 1,021 48.4 (10.7) 0.805 5.8x10-5 
Number of 
Positive Lymph 
Nodes     
Asian/PI 490 48.1 (10.1) 1.000 0.275 0 3,737 48.2 (10.3)   
Other 237 46.6 (10.7) 0.631 0,184 1 or 2 1,587 47.5 (10.5) 0.152 0.305 
Education     >=3 1,413 46.7 (10.5) <0.001 0.186 
HS or Less 2,516 47.3 (11.0)  
 Receptor 
Subtype     
Voc/AA 2,685 47.2 (10.6) 1.000 0.187 HmR-positive 4,434 48.2 (10.3)   
College  4,548 48.4 (9.9) <0.001 1.1x10-5 HER2-positive 995 46.8 (10.6) 0.001 0.050 
Alcohol     Triple-negative 943 46.6 (10.9) <0.001 0.079 
Never 4,897 48.2 (10.5)   Menopause     
Former 757 45.3 (10.6) <0.001 3.9x10-6 Premenopause 4,017 48.4 (10.5)   
Current 4,418 47.7 (10.2) 0.106 0.008 Perimenopause 2,586 46.7 (10.3) <0.001 0.546 
Smoking      Postmenopause 191 47.3 (10.8) 0.565 0.509 
Never 6,566 48.4 (10.1)   Diagnosis Year     
Former 2,708 47.4 (10.4) <0.001 0.002 1999-2002 722 47.1 (10.7)   
Current 820 43.7 (11.6) <0.001 6.4x10-11 2003-2007 2,593 47.6 (10.7) 0.522 0.430 
Marital Status     2008-2012 3,492 48.0 (10.2) 0.101 0.232 
Married 7,210 48.1 (10.1)   Histology     
Never Married 1,214 46.8 (10.8) <0.001 0.056 Ductal 5,421 47.5 (10.5)   
Other 1,765 47.0 (11.2) <0.001 1.8x10-5 Lobular 584 48.6 (10.1) 0.127 0.339 
Past Medical 
History Score    
 Mixed 
Ductal/Lobular 402 48.2 (10.2) 0.765 0.287 
0 2,952 48.5 (9.9)   Other 400 48.4 (10.2) 0.576 0.481 
1 3,063 48.2 (10.3) 0.825 0.034      
2 2,180 47.4 (10.6) 0.001 5.3x10-11      
≥3 2,002 46.3 (11.0) <0.001 1.1x10-21      
Previous 
Treatment    
 
     
None 5,876 47.9 (10.4)        
Yes 4,321 47.6 (10.4) 0.086 0.446    
Stage         
I 1,517 48.4 (10.3)  
 
    
II 2,071 47.8 (10.4) 0.382 0.183     
III 890 46.5 (11.3) <0.001 0.885     
*Adjusted 
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3.3.6. Distribution of Determinants of QOL by Race 
      As shown in Table 8, there are racial disparities in PCS. To better understand the 
underlying explanation, we showed the distribution of determinants of PCS score by race 
(Figure 8). Fifty-six percent of Hispanics, 56% of Asian/PIs and 60% of Black patients 
discovered their breast cancer based on symptoms, which is a higher percentage compared to 
how White patients detected their cancer (50%) (Figure 8A). In addition, Black patients whose 
breast cancer was diagnosed based on symptoms reported on average an almost 5 point lower 
PCS score compared to Asian/PIs who were diagnosed based on symptoms (Figure 8A). 
Marital status was a strong predictor of a good QOL, with married patients reporting higher 
scores. When examining the distribution of marital status by race, Black patients had the lowest 
percentage of currently married patients at only 47%, compared to 80% of Asian/PI being 
married and 74% of White patients (Figure 8B) and Black and Hispanic patients reported lower 
PCS scores in the “Never Married” and “Other” group as well. An increasing trend in the 
percentage of patients with a high school diploma or less (a group that reported lower PCS 
scores) from Asian/PI (16%), White (23%), Black (29%), and Hispanic patients (44%) was seen 
(Figure 8C). When examining PCS scores by race in the patients who had completed high 
school or less, Blacks reported an average 6 points lower compared to Asian/PI (Figure 8C). 
When examining clinical characteristics, Hispanics had the largest proportion of patients who 
had three or more lymph nodes positive for cancer (26%) followed by Blacks (24%) (Figure 
8D). Asian/PI had the lowest proportion of patients with three or more positive lymph nodes 
(18%) and those in that group reported higher PCS scores compared to other races in that 
group. 
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Figure 9. Distribution of determinants of QOL by race and corresponding QOL scores; 
A) Cancer detection mode by race B) Marital status by race C) Education by race D) 
Number of cancer positive lymph nodes by race 
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3.4. Discussion 
      The present study first examined the relationship between QOL and survival/recurrence in 
breast cancer patients. In the first section of the study, we found a dose response relationship 
between PCS score and survival. As PCS score decreased, the risk of death increased. For the 
second part of the study, predictors of QOL were analyzed and we aimed to further understand 
how the predictors of QOL were distributed by race. Significant predictors of a low PCS score 
included Hispanic and Black races, a higher BMI, never being married, finding breast cancer 
based on symptoms, having a nuclear III grade tumor, and triple-negative receptor status. 
Hispanic patients had the largest percentage of discovering their breast cancer due to 
symptoms, had the largest percent of patients with a high school degree or less, and were 
more likely to have three or more lymph nodes positive for breast cancer. Blacks had the 
lowest proportion of being married and Black patients who were “Never Married” or were in the 
“Other” group (separated, widowed, or divorced) and reported the lowest PCS scores 
compared to patients of other races in those groups. Asian/PI patients had the largest 
percentage of patients who were married and had the highest proportion of college educated 
patients and patients in these groups also reported the higher PCS scores. This is the first 
study to our knowledge that has comprehensively examined QOL predictors by race in newly 
diagnosed breast cancer patients. The results of this study can potentially be used to provide 
more data for patients that would identify from QOL interventions.  
      The current research on QOL in breast cancer patients does not include many studies on 
QOL and recurrence. One study found that better social well-being at diagnosis was associated 
with lower recurrence in breast cancer patients, but other domains of QOL and overall QOL 
were not associated with recurrence.(119) Other domains examined in that study included 
physical QOL, and while not significant due to a small number of events, the effect size was 
similar to our results(119). Specifically, a better physical QOL was associated with a reduced 
risk of recurrence(119). A benefit of examining recurrence in breast cancer patients is that the 
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outcome is specific. When examining survival in this study, we examined overall survival, which 
was not specific to breast cancer.  
      Previous studies have examined QOL around the time of breast cancer diagnosis and 
survival. For example, using data from the Shanghai Breast Cancer Survivor Study, one study 
found that breast cancer patients with a higher social well-being had a 38% decreased risk of 
death, but other QOL domains (physical, material, and psychological) were not associated with 
death(119). Social functioning is a subscale on the SF-12 and goes into calculating the MCS 
score. The MCS in our study were not significantly associated with survival, but a potential next 
step would be to look at subscales of the SF-12 individually. Other studies have examined 
domains of physical QOL. For example, in multivariate survival analyses, role function (the 
ability to perform normal daily activities) was significantly associated with survival(182). Another 
study found that physical QOL after disease relapse was associated with survival, specifically 
better physical well-being was associated with survival one month after relapse and six months 
after relapse. But that study did not find that baseline QOL was associated with survival(159). 
Our analysis showed that physical QOL was associated with overall survival. And specifically a 
dose response was seen, as QOL score decreased the risk of death increased. Our study used 
a comprehensive physical QOL score (the PCS) that encompasses many domains of physical 
QOL(58). The majority of previous studies regarding QOL and survival in breast cancer 
patients utilized domains of physical QOL rather than a comprehensive score.  
      Few studies have comprehensively examined predictors of QOL in breast cancer patients 
that are measured around the time of diagnosis. One study out of Munich examined predictors 
of QOL in breast patients within one year of their diagnosis with a sample size of 990 patients. 
But that study aimed to examine the simultaneous long-term effects of arm morbidity, 
communication, and comorbid conditions on long-term QOL and was not a comprehensive 
analysis(183). Another study examining predictors of QOL in breast and melanoma patients 
took a more psychological point of view and examined more of the psychological predictors of 
QOL (for example, predictors in the stress process and escape-avoidance coping were 
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associated with QOL)(184). One of our interesting results showed that patients who were never 
married reported lower physical QOL compared to their married counterparts. To our 
knowledge, this specific finding has not been reported before in the literature though there have 
been multiple studies on the benefits of marriage to the diagnosis and survival of breast 
cancer(185-187). One study that examined QOL predictors in a large sample of patients 
diagnosed with breast, urological, gastrointestinal, and gynecologic cancers found that non-
married patients reported more depressive symptoms (a domain of QOL) compared to married 
patients or patients who lived with their partner(83). And another study reported that married 
breast cancer patients reported better social/family well-being and functional well-being QOL 
scores(188). 
      When we examined clinical factors, triple-negative breast cancer was a predictor of poor 
PCS score in unadjusted analyses. Triple-negative breast cancer is an aggressive subtype with 
poorer outcomes compared to other receptor subtypes. However, one study published on 
predictors of QOL in newly diagnosed breast cancer patients did not find any association 
between triple-negative breast cancer and QOL using the Functional Assessment of Cancer 
Therapy – Breast Cancer (FACT-B) questionnaire(188). Patients with triple-negative breast 
cancer are usually diagnosed with later stage disease and more aggressive disease, leading to 
more physical symptoms and limitations. When considering racial disparities, studies show that 
Black women are more likely to be diagnosed with triple-negative breast cancer(189). And we 
had found in our study that Black patients also reported worse PCS scores. The relationship 
between racial disparities and breast cancer is a complicated issue that needs further research.  
      We showed race is associated with poor survival, specifically that Black patients had worse 
overall survival and Asian/PI had the best survival, which is consistent with the literature(190). 
In addition, we found that QOL differed by race. We wanted to examined how determinants of 
QOL were distributed by race and subsequently how QOL scores differed by race and 
determinants to be able to more specifically identify patients at risk for poor QOL. When we 
examined how predictors of PCS score were distributed, we found intriguing results. First, 
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Black, Hispanic, and Asian/PI patients were more likely to have discovered their breast cancer 
based on symptoms instead of routine screening. Breast cancer screening rates have been 
shown to differ among races and this can partially be due to access to healthcare 
screenings(191, 192), which could potentially lead to women seeking treatment for breast 
cancer symptoms rather than seeing a physician on a regular basis for screening. To the best 
of our knowledge, there have not been any studies published on the distribution of women who 
discover their breast cancer via screening or symptoms and any association with physical QOL. 
In our study, Black and Hispanic women who discovered their cancer based on symptoms 
reported on average lower PCS scores compared to Whites and Asian/PI who discovered their 
cancer by symptoms. We hypothesize that this relationship could be due to the symptom 
burden that is experienced by breast cancer patients, which can be worse for Hispanic and 
Black women(193). Research also shows that a better QOL (including physical QOL) is 
predictive of a woman receiving her screening mammogram(194). Furthermore, another study 
found that older Black cancer patients were more at risk for depression if they had cancer 
symptoms (not specific to breast cancer) compared to asymptomatic patients(195). It is 
apparent that this finding is complicated and more research is needed. Potential next steps 
would be to look prospectively at what comes first, poor QOL across racial minorities which 
leads to poor screening for cancer, or the reverse.  
      Other predictors of PCS score that differed in distribution by race group included marital 
status and education. Marital status has been indicated as an important part of social support 
during cancer with impacts on QOL and cancer survival(186, 196-198). Our study showed that 
never married, separated, widowed, or divorced Black patients reported a lower PCS score and 
Blacks had the largest percentage of unmarried patients indicating a potential lack of social 
support. A study that examined predictors of QOL across races in breast cancer survivors 
found that social support is an important predictor of QOL across races except for Asian 
Americans(199). Education level was also a predictor of a poor PCS score in our study. 
Further, Hispanic and Black patients had the largest percentage of patients with a high school 
73 
 
degree or less and those patients reported lower QOL scores. Education level is considered a 
proxy for SES, and research has shown that breast cancer survivors that have a lower SES 
report lower QOL(200). These findings could be used to target interventions in racially diverse 
groups in the future with the intent of improving QOL and potentially survival.  
      Two major strengths of this study are the large sample size and the very detailed host and 
clinical characteristic data. Also, a large amount of follow-up time data was available. A 
potential limitation of this study is the lack of information on arm mobility due to surgery that 
may have removed lymph nodes and resulting lymphedema which could negatively impact 
QOL.  
      The findings of our study show that poor physical QOL and being Black or Hispanics are 
associated with poor survival and recurrence in breast cancer patients. To further examine the 
reasons underlying these associations, we found that a high BMI, being unmarried, detecting 
breast cancer based on symptoms, triple negative receptor subtype, and a high nuclear grade 
(among other factors) were predictors of poor physical QOL. Further, these determinants were 
disproportionally distributed more among Black or Hispanic patients. The results of this study 
highlight the importance of understanding racial disparities in cancer survival and the potential 
factors that may impact cancer survival. Potential interventions on cancer patients could be 
planned for future research that would target modifiable factors (such as obesity) with the 
hopes of improving QOL and cancer survival. 
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Chapter 4. Genetic Variants in the Dopaminergic System and Bladder 
Cancer Clinical Outcomes 
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4.1. Introduction 
      Bladder cancer is the fourth most common cancer and ranks eighth in cancer related death 
for men in the United States in 2017(1). Approximately 80% of patients are diagnosed with non-
muscle invasive bladder cancer (NMIBC) and 50-80% will experience a recurrence, with 
approximately 14% of those patients going on to progress to muscle invasive bladder cancer 
(MIBC)(77). The standard initial treatment for NMIBC is transurethral resection (TUR). To 
reduce the risk of recurrence caused by tumor cell implantation following TUR, perioperative 
intravesical therapy is often given(201). Bacillus Calmette-Guerin (BCG) is the intravesical 
therapy most commonly given with the goal of delaying recurrence or progression of 
disease(72, 73). It is an immunotherapy that is thought to mount a local immune response(73). 
Though BCG is considered the gold standard for treatment of high-risk NMIBC, a subset of 
patients experience negative side effects (such as cystitis, increased urine frequency, 
hematuria, and fever)(202). Treatment for MIBC usually entails removal of the bladder and/or 
chemotherapy/radation(74). Even after radical cystectomy in MIBC patients, half of patients will 
go on to develop metastasis and will die within 2-years(203). Management decisions for 
bladder cancer patients are based on clinical and pathological factors including number of 
tumors, the size of the tumors, prior recurrence, tumor grade, depth of invasion into the bladder 
wall, and the presence of carcinoma in situ (CIS)(204). Therefore, the defining feature of 
bladder cancer is the unfavorable clinical outcomes, specifically the high recurrence rate 
experienced by NMIBC patients. The identification of accurate predictive biomarkers are 
urgently needed to identifying patients who are at a higher risk of a poor clinical outcomes. 
Results in this area could guide future treatment and surveillance guidelines. 
      Currently, there lacks good molecular markers predictive of bladder cancer clinical 
outcomes. One area of biomarker interest is in genetics. Evidence supports a heritability to 
bladder cancer risk(66, 205). Currently, many bladder cancer susceptibility loci have been 
identified through large scale genome wide association study(206-210). But there are fewer 
studies that examined the association of genetic variants with bladder cancer clinical 
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outcomes(113, 209, 211). Several pathways have been examined for their association with 
bladder cancer outcomes such as the microRNA biogenesis pathway, the DNA repair pathway, 
detoxification pathways, and angiogenesis(212, 213). A recent study showed a validated single 
nucleotide polymorphism (SNP) in the micro-RNA biogenesis gene DDX20 associated with a 
decreased risk of recurrence in NMIBC patients who have received TUR(213). This study used 
bootstrapping to internally validate SNP rs197412 and was also able to additionally validate the 
findings using a separate population and this variant was borderline significant(213). Other 
genes that have SNPs associated with bladder cancer clinical outcomes include ERCC4, 
EPHX1, and CXCR2. Variants in these genes have been associated with survival in MIBC 
patients, though these appear to not have gone through a validation phase of study(212). In 
addition, studies have also looked at treatment specific variants and the association with 
bladder cancer outcomes. For example, SHH: rs1233560 and GLI2: rs11685068 are 
associated with recurrence in NMIBC patients that receive TUR-only(209). Also, in bladder 
cancer patients that receive chemotherapy, multiple polymorphisms in XRCC1 were protective 
for survival(214). A recent study by Lin et al. found that bladder cancer patients that are 
depressed at time of diagnosis show a worse survival(101), which leads to the question: Is 
there is a genetic component in patients with bladder cancer that also plays a role in 
depression?  
      The dopaminergic system plays a role in cognition, depression, addiction, pleasure, reward, 
and working memory(114). This system is also thought to play a role in immune function, as 
well as cancer growth(215). Further, smoking is one of the major risk factors for bladder 
cancer(61) and the dopamine system plays a major role in nicotine addiction(216-218). In 
addition, dopamine has a complex interaction in the brain with glutamate and GABA 
neurotransmission in the reward circuit(219). There are five subtypes of dopamine receptors 
encoded by the human genes DRD1, DRD2, DRD3, DRD4, and DRD5 that control the majority 
of the physiological functions of dopamine(220). These receptors also impact cardiovascular, 
renal, and gastrointestinal functions(220). There are not many studies that have examined 
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genetic variants in the dopamine pathway and bladder cancer. One study that examined SNPs 
from major pathways involved in the carcinogenesis pathway did find a variant in DRD4 to be 
associated with survival in bladder cancer patients, though this study did not do an in-depth 
analysis of variants in and related to dopamine(221). In this study, we aimed to perform a 
comprehensive analysis of genetic variants in the dopaminergic system and examine their 
associations with bladder cancer clinical outcomes utilizing the largest on-going bladder cancer 
epidemiology study in the United States – the Texas Bladder Cancer Study (TXBCS). We also 
assessed if there were associations between these genetic variants and clinical outcomes 
stratified by treatment regimens. We used a two-phase study design with a discovery and an 
external validation phase using an independent population. To our knowledge, this is the first 
study to comprehensively examine the associations between genetic variants in the dopamine 
pathway and bladder cancer clinical outcomes. 
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4.2. Methods 
4.2.1. Study Subjects 
      Bladder cancer patients were recruited from The University of Texas MD Anderson Cancer 
Center and Baylor College of Medicine from 2007 to 2012. Patients were identified by trained 
study staff members from daily clinic schedules. Patients were diagnosed with histologically 
confirmed transitional cell carcinoma bladder cancer and were untreated. There were no 
restrictions in terms of age, sex, or stage of bladder cancer. All participants provided written 
informed consent prior to data and biospecimen collection and the Institutional Review Boards 
of MD Anderson Cancer Center and Baylor College of Medicine approved this study. Over 90% 
of recruited patients were Caucasian, therefore the analyses were limited to Caucasian patients 
to reduce the confounding effect of population structure.   
      An independent validation was completed using an on-going bladder cancer study in 
Europe: The Spanish Bladder Cancer (SBC)/Epidemiology of Cancer of the Urothelium 
(EPICURO). The SBC/EPICURO study recruited NMIBC and MIBC patients between 1998 and 
2001 across 18 different hospitals (either general or university-affiliated) in five different 
geographical regions in Spain.  
4.2.2. Data Collection  
      Recruited TXBCS patients completed an in-person interview with a trained staff member. 
The interview asked questions pertaining to age, sex, smoking history, occupational history, 
family medical history, personnel medical history, and nutrition. Current smokers were patients 
who had smoked at least one cigarette in the previous year. Former smokers were those who 
had not smoked one cigarette in the past year and never smokers were cases who had 
smoked less than 100 cigarettes in his or her lifetime. Clinical variables were abstracted from 
electronic medical records by trained staff. For the SBC/EPICURO study, trained interviewers 
conducted personal computer-assisted questionnaires at first hospital admission to collect 
sociodemographic and symptom data(222). Clinical data (diagnostic procedures, first 
79 
 
treatment, stage, and tumor characteristics) was abstracted by physicians using a structured 
questionnaire(222).  
4.2.3. SNP Selection and Genotyping  
      For the discovery phase, patients provided a 40 milliliter (mL) peripheral blood sample at 
time of study recruitment to be used for genetic analyses. Genes related to the dopamine 
system were identified through KEGG and Reactome databases using the search words 
“dopamine” and “dopaminergic”. SNPs were within 10 kb from the start and end of gene 
transcription. For this study, 3,099 genetic variants in 178 genes were analyzed. The genotype 
data used for this study was from a previously completed genome-wide association study 
(GWAS) on bladder cancer. Detailed genotyping and quality control procedures were 
previously described(210). Briefly, the GWAS was completed using the Illumina’s Human-
Hap610 BeadChip following the manufacturer protocol. Beadstudio software (Illumina) was 
used to export and analyze the genotyping data. The SBC/EPICURO validation SNPs were 
genotyped using the Infinium Illumina Human 1M probe BeadChip(209).  
4.2.4. Statistical Analysis 
      The majority of the statistical analyses were performed using Stata 14 statistical software 
package (Stata Corporation, College Station, TX). Host characteristics (demographic and 
clinical variables) were analyzed using the Pearson’s χ2 test or Fisher’s exact test if the 
variables were categorical and the Wilcoxon rank sum test or student’s t-test if the variables 
were continuous. Goodness-of-fit χ2 analysis was used to test Hardy-Weinberg equilibrium. To 
analyze if there was an association between SNPs related to the dopamine pathway and 
bladder cancer clinical outcomes, multivariate proportional Cox regression was used. Hazard 
ratios (HR), 95% confidence intervals (CI), and p-values were calculated in the dominant, 
recessive, and additive model of genetic inheritance. Models were adjusted for age, gender, 
sex, smoking status, grade of disease, stage of disease, and treatment. Stratified analyses by 
treatment groups were conducted to examine whether the effect of genetic variants on clinical 
outcomes were modified by the treatment groups. The endpoints for this study were recurrence 
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and progression for NMIBC patients and survival for MIBC and metastatic patients. Recurrence 
was defined as having a recurring tumor following a cancer free cystoscopy. Progression was 
defined as progressing from a NMIB tumor to a MIB tumor. Time to event was calculated from 
date of diagnosis to date of event, or last contact, or death, whichever came first.  Kaplan-Meier 
curves were generated for validated SNPs. Median recurrence time (MRT), median 
progression time (MPT), and median survival time (MST), and log-rank tests were calculated 
for patients stratified by each validated SNP. SNPs that had a p-value of less than 0.005 in the 
discovery phase of TXBCS were followed up in an independent population (SBC/EPICURO) for 
validation. In the validation, multivariate proportional Cox regression was used to analyze the 
association between SNPs and bladder cancer clinical outcomes.  
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4.3. Results 
4.3.1. Host Characteristics 
      The patient characteristics are shown in Table 10. The median follow-up time for NMIBC 
patients with recurrence or progression was 78.2 months and 80.6 months, respectively. The 
median follow-up time for MIBC patients was 90.1 months. In total, there were 503 patients with 
NMIBC and 388 patients with MIBC (which includes patients with stage IV metastatic disease). 
When examining the NMIBC group, 270 patients experienced a recurrence and 94 patients 
experienced progression of disease. The majority of NMIBC patients were male and former 
smokers. The mean age in those who experienced a recurrence was 62.5. When examining 
recurrence, the majority of patients who had Ta disease and were high grade experienced a 
recurrence. There was a significant difference in those who had a recurrence and those who 
did not based on treatment. There were 153 patients in the maintenance BCG (mBCG) 
subgroup and 107 patients in the induction BCG (iBCG) subgroup.  Those who had iBCG 
therapy only (and did not complete maintenance BCG therapy) had the highest number of 
recurrences. When examining progression, significant differences were seen for sex and age 
(P=0.037 and P=0.023, respectively). In the MIBC group, the majority of patients were male 
and former smokers as well. The mean age in patients who died was 67.6, which was 
significantly higher than those who were alive (61.9, p<0.001). There was a significant 
difference in survival status based on grade of disease, with the largest number of deceased 
patients having high grade (G3) disease.  
 
 
 
 
 
 
 
82 
 
 
 
 
 
Table 10. Host Characteristics in NMIBC and MIBC Patients     
   NMIBC (N=503)   MIBC (N=388)  
 Recurrence N (%) Progression N(%) Survival N(%) 
Characteristic 
Yes  
(N=270) 
No   
(N=233) P Value 
Yes 
(N=94) 
No     
(N=409) P Value 
Dead 
(N=230) 
Alive    
(N=158 P Value 
Sex           
Male 224 (54.4) 188 (45.6)  84 (20.4) 328 (79.6)  172 (58.7) 121 (41.3)  
Female 46 (50.6) 45 (49.5) 0.508 10 (11.0) 81 (89.0) 0.037 58 (61.1) 37 (39.0) 0.685 
Age (years)           
Mean (SD) 62.5 (11.4) 63.1 (12.0) 0.587 65.2 (9.1) 62.2 (12.1) 0.023 67.6 (10.8) 61.9 (10.0) <0.001 
Smoking Status           
Never 81 (54.7) 67 (45.3)  28 (18.9) 120 (81.1)  42 (52.5) 38 (47.5)  
Former 113 (54.3) 95 (45.7)  43 (20.7) 165 (79.3)  116 (63.4) 67 (36.6)  
Current 64 (54.2) 54 (45.8) 0.996 22 (18.6) 96 (81.4) 0.876 66 (57.4) 49 (42.6) 0.226 
T Stage           
Ta 128 (57.4) 95 (42.6)  25 (11.2) 198 (88.8)  -- --  
Tis 22 (66.7) 11 (33.3)  10 (30.3) 23 (69.7)  -- --  
T1 119 (48.4) 127 (51.6) 0.044 58 (23.6) 188 (76.4) 0.001 -- --  
T2 -- --  -- --  139 (52.9) 124 (47.2)  
T3 -- --  -- --  40 (63.5) 23 (36.5)  
T4 -- --  -- --  48 (88.9) 6 (11.1) <0.001 
Grade           
G1 8 (36.4) 14 (63.6)  1 (4.6) 21 (95.5)      
G2 95 (54.6) 79 (45.4)  13 (7.5) 161 (92.5)  4 (30.8) 9 (69.2)  
G3 151 (52.4) 137 (47.6) 0.272 72 (25.0) 216 (75.0) <0.001 218 (60.2) 144 (39.8) 0.034 
Treatment NMIBC           
TUR 102 (62.2) 62 (37.8)  20 (12.2) 144 (87.8)  -- --  
iBCG 116 (75.8) 37 (24.2)  46 (30.1) 107 (69.9)  -- --  
mBCG 36 (33.6) 71 (66.4)  24 (22.4) 83 (77.6)  -- --  
Other 16 (20.3) 63 (79.8) <0.001 4 (5.1) 75 (94.9) <0.001 -- --  
Treatment MIBC          
TUR+Cystectomy -- --  -- --  52 (44.4) 65 (55.6)  
TUR+Chemotherapy -- --  -- --  59 (58.4) 42 (41.6)  
TUR+Cystectomy 
+Chemotherapy -- --  -- --  44 (88.0) 6 (12)  
TUR  Only -- --  -- --  32 (74.4) 11 (25.6)  
Other -- --  -- --   39 (55.7) 31 (44.3) <0.001 
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4.3.2. Association between Dopamine Pathway SNPs and Recurrence and Progression 
of Bladder Cancer in NMIBC Patients 
Recurrence  
      When analyzing the association between dopamine pathway SNPs and recurrence in 
NMIBC patients, 37 SNPs were significant with a p-value less than 0.005. However, none of 
the SNPs were validated in the independent SBC/EPICURO population.  
Progression 
      A total of 24 SNPs were associated with progression in NMIBC patients. Three variants 
located in the Synaptotagmin 1 gene (SYT1) were validated (rs10861755, rs1245810, 
rs1245819) (Table 11). The three variants were in high linkage disequilibrium with an R2=1.00 
for rs10861755 and rs1245810, an R2=0.99 for rs10861755 and rs1245819, and a R2=0.98 for 
rs1245810 and rs1245819. The most significant variant associated with progression was 
rs1245819 (Discovery: HR=2.35, 95% CI: 1.34-4.11, P=0.003; Validation: HR=2.14, 95% CI: 
1.18-3.89, P=0.013). The results of the meta-analysis was significant (HRMeta:2.25, 95% CI: 
1.50-3.38, P=0.0001) (PHeterogeneity=0.82). The PLog-rank test was significant (PLog-rank=0.0008) and 
the MPT was not able to be calculated (Figure 9).  
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Table 11. Genetic Variants in the Dopamine Pathway and Progression in NMIBC Patients 
 
      Discovery       Validation       Meta-Analysis  
 
Gene: SNP Model 
Minor 
Allele Progression  
No 
Progression HR (95% CI)* 
P 
Value Progression 
No 
Progression HR (95% CI)** 
P 
Value HR (95% CI) 
P 
Value PHeterogeneity 
SYT1: 
rs10861755 Rec G 94 409 2.35 (1.34-4.11) 0.003 83 752 2.02 (1.13-3.62) 0.017 2.19 (1.46-3.27) 0.0001 0.71 
SYT1: rs1245810 Rec A 94 409 2.35 (1.34-4.11) 0.003 83 752 1.88 (1.03-3.43) 0.038 2.12 (1.41-3.19) 0.0003 0.59 
SYT1: rs1245819 Rec G 94 409 2.35 (1.34-4.11) 0.003 83 752 2.14 (1.18-3.89) 0.013 2.25 (1.50-3.38) 0.0001 0.82 
*Adjusted for age, sex, smoking, grade, treatment, and stage 
**Adjusted for gender, age, and region    
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Figure 10. Kaplan-Meier curves of validated variants and progression in NMBIC patients; 
A) SYT1: rs10861755 B) SYT1: rs1245810 C) SYT1: rs1245819 
 
A) B) C) 
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4.3.3. Genetic Predictors of Survival in MIBC Patients 
      Overall, 37 SNPs were associated with survival in MIBC patients at a p-value cut-off of 
0.005. When comparing the results with the SBC/EPICURO population, no variants were 
validated. 
4.3.4. Genetic Predictors of Recurrence and Progression in the TUR Only Group 
Recurrence 
      A total of 47 SNPs in the discovery phase were significantly associated with recurrence in 
NMIBC patients that received TUR only. No variants were validated in the independent 
population.  
Progression 
      Overall, 26 SNPs were significantly associated with progression in the discovery phase 
analysis in NMIBC patients only treated with TUR. Using the SBC/EPICURO population, one 
variant was validated (Table 12). In the discovery phase, patients with two copies of variant 
allele of SLC1A1: rs7848533 showed an almost six-fold (HR: 5.93, 95% CI: 2.05-17.15, 
P=0.001) increased risk of progression compared to patients who were wildtype or 
heterozygous. In the validation population, patients showed an almost three-fold (HRSBC/EPICURO: 
2.78, 95% CI: 1.36-5.68, P=0.005) increased risk of progression. This SNP was significant in 
the meta-analysis as well (HRMeta=3.52, 95% CI: 1.95-6.37, P=0.000032) (PHeterogeneity=0.25). 
The MPT was not able to be calculated as not enough people experienced progression. The 
KM curve was calculated (Figure 10) and a significant difference was seen between those who 
were in the wildtype/heterozygous groups versus the homozygous variant group (PLog-
rank=0.0005). 
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Table 12. The Association Between Dopamine SNPs and Progression in NMIBC Patients that Received TUR-Only         
 
   Discovery    Validation    Meta-Analysis   
Gene: SNP Model 
Minor 
Allele Progression 
No 
Progression HR (95% CI)* 
P 
Value Progression 
No 
Progression HR (95% CI)** 
P 
Value HR (95% CI) P Value PHeterogeneity 
SLC1A1: 
rs7848533 Rec C 20 144 5.93 (2.05-17.15) 0.001 34 321 2.78 (1.36-5.68) 0.005 3.52 (1.95-6.37) 3.2x10-5 0.25 
*Adjusted for age, sex, smoking, grade, treatment, and stage 
**Adjusted for age, sex, and region      
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Figure 11. Kaplan-Meier curve of validated rs7848533 and progression in NMIBC patients 
that Received TUR   
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4.3.5. Genetic Predictors of Recurrence and Progression in the BCG Group 
Recurrence 
      A total of 50 SNPs were associated with recurrence in NMIBC patients who had received 
BCG therapy in the discovery phase and one SNP was validated in the SBC/EPICURO 
population. The most significant result was PLCB4: rs6133707 which was associated with a 
4.32-fold increased risk of recurrence (HR=4.32, 95% CI: 2.16-8.64, P=0.00004) in patients 
with two copies of the variant allele in the discovery phase. In the SBC/EPICURO validation 
phase, NMIBC patients with the homozygous variant allele showed an almost 4-fold increased 
risk of recurrence (HRSBC/EPICURO=3.99, 95% CI: 1.86-8.57, P=0.0004) (Table 13). The results of 
the meta-analysis of the discovery and validation were significant (HRMeta=4.17, 95% CI: 2.49-
6.96, P=0.00000005) (PHeterogeneity=0.88). When analyzing the KM curve, patients with wildtype 
or one copy of the variant allele had a MST of 15.8 months compared to 5.0 months for 
patients with two copies of the variant allele (PLog-rank=0.002) (Figure 11A). 
Progression 
      There were 38 SNPs associated with progression in NMIBC patients who received BCG 
therapy. Three variants were validated in the SBC/EPICURO population. After adjusting for 
potential confounders, patients with two variant alleles of CAMK2A: rs3776825 had an 
increased risk of progression (HR: 3.87, 95% CI: 1.90-7.89, P=0.0002) (Table 13). The KM 
curve (Figure 11B) showed a significant difference in median progression time for patients with 
two copies of the variant allele and patients who are wildtype or heterozygous (PLog-
rank=0.0007), with patients who have two copies of the variant allele having a median 
progression time of 88.9 months. The variant rs3776825 in CAMK2A was validated and was 
found to show an increased risk of progression in patients who have BCG therapy 
(HRSBC/EPICURO=3.74, 95% CI: 1.58-8.87, P=0.003) (HRMeta=3.82, 95% CI: 2.20-6.61, 
P=0.000002) (PHeterogeneity=0.95) (Table 13). Two linked variants (R2=0.99) SYT1: rs10861755 
and SYT1: rs1245810 were associated with an increased risk of progression in BCG treated 
patients (HR: 2.91, 95% CI: 1.62-5.22, P=0.0004). The KM curves showed that patients with 
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two copies of the variant have a MPT of 88.9 Months (PLog-rank=0.0007) (Figure 11C and 11D). 
These variants validated using the SBC/EPICURO population and showed an almost 400% 
increase risk of progression (HRSBC/EPICURO=3.78, 95% CI: 1.48-9.65), P=0.006) with the meta-
analysis results also significant (HRMeta=3.13, 95% CI: 1.91-5.14, P=0.000007) 
(PHeterogeneity=0.64) (Table 13). 
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Table 13. Genetic Variants in the Dopamine Pathway and Recurrence and Progression in NMIBC Patients Who Received BCG Therapy 
   
 
   Discovery    Validation    Meta-Analysis   
Gene: SNP Model 
Minor 
Allele Recurrence 
No 
Recurrence HR (95% CI)* P Value Recurrence 
No 
Recurrence HR (95% CI)** P Value HR (95% CI) P Value PHeterogeneity 
PLCB4: 
rs6133707 
Rec G 152 108 4.32 (2.16-8.64) 4.0x10-5 69 200 3.99 (1.86-8.57) 0.00038 4.17 (2.49-6.96) 5.0x10-8 0.88 
   Discovery    Validation    Meta-Analysis   
Gene: SNP Model 
Minor 
Allele Progression 
No 
Progression HR (95% CI)* P Value Progression 
No 
Progression HR (95% CI)** P Value HR (95% CI) P Value  
CAMK2A: 
rs3776825 
Rec A 70 190 3.87 (1.90-7.89) 0.00019 30 239 3.74 (1.58-8.87) 0.003 3.82 (2.20-6.61) 2.0x10-6 0.95 
SYT1: 
rs10861755 
Rec G 70 190 2.91 (1.62-5.22) 0.0004 30 239 3.78 (1.48-9.65) 0.0055 3.13 (1.91-5.14) 7.0x10-6 0.64 
SYT1: 
rs1245810 
Rec A 70 190 2.91 (1.62-5.22) 0.0004 30 239 3.78 (1.48-9.65) 0.0055 3.13 (1.91-5.14) 7.0x10-6 0.64 
*Adjusted for age, sex, smoking, grade, treatment, and stage 
**Adjusted for age, sex, and region 
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Figure 12. Kaplan-Meier curves of validated genetic variants Associated with recurrence 
and progression in NMIBC patients who received BCG therapy; A) PLCB4: rs6133707 B) 
CAMK2A: rs3776825 C) SYT1: rs10861755 D) SYT1: rs1245810 
 
 
 
 
 
 
 
 
A) B) 
C) D) 
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4.4. Discussion 
      The novel results of this study have the potential to aid in clinical decision making for 
patients with bladder cancer. Three highly linked SNPs in the dopamine pathway were 
associated with an increased risk of progression in NMBIC patients and were validated in the 
SBC/EPICURO population. Further, SLC1A1: rs7848533 was validated in the SBC/EPICURO 
population when examining the association with progression in patients who received TUR 
only, and was found to have an almost 6-fold increased risk of progression in the discovery 
phase and an almost 3-fold increased risk of progression in the validation phase. Finally, when 
restricting the analysis to patients who received BCG therapy, one variant was validated in the 
SBC/EPICURO population for risk of recurrence, and three variants validated for risk of 
progression. The validated SNPs based on the stratified analysis for treatment subgroups have 
the potential as the predictive biomarkers that could be used to identify high risk patients for 
more frequent monitoring or alternative treatment strategies. This is the first study to examine 
the association between genetic variants in the dopamine pathway and bladder cancer clinical 
outcomes. 
      The most significant SNPs associated with progression were all located in SYT1. NMIBC 
patients with two variants of rs10861755, rs1245810, or rs1245819 had a higher risk of 
progression. Furthermore, two of them (rs10861755 and rs1245810) were also associated with 
an increased risk of progression in patients who had received BCG therapy. These variants 
were not associated with progression in patients that received TUR-only and the effect size 
was not in the same direction. The gene SYT1 encodes the protein Synaptotagmin 1, which 
plays a critical role in regulating neurotransmitter release in neurons(223-225). There is 
evidence that SYT1 has a potential role in liposarcoma(226) but there has been no evidence of 
a role in bladder cancer. These variants are located on chromosome 12 and are intronic. More 
research is needed to understand the mechanism of these associations. Future steps include 
understanding the potential functional role of these variants.  
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      When we examined progression in bladder cancer patients who received TUR only, 
rs7848533 in SLC1A1 showed the highest risk of progression in patients with two copies of the 
variant allele. The results of our study are the first, to our knowledge, to examine the role of 
SLC1A1 and bladder cancer. SLC1A1 is a neuronal glutamate transporter that encodes EAAT3 
(the excitatory amino acid transporter)(227) and glutamatergic input in specific regions of the 
brain cancer increases the activity of dopaminergic cells and increase dopamine release(228, 
229). While mutations in this gene have been associated with mental health illness such as 
obsessive compulsive disorder(230), there are not many studies examining SLC1A1 and its 
association with cancer. But the neurotransmitter that SLC1A1 transports, glutamate, has been 
associated with cancer in the brain(231, 232) and other tissues (233, 234). The mechanism 
behind the association of rs7848533 and bladder cancer progression in TUR-only patients is 
not clear, but SLC1A1 is expressed in bladder tissue providing evidence for a potential role in 
bladder cancer(235). Further studies are warranted. 
      Patients with NMIBC who had two copies of variant allele PLCB4: rs6133707 and who had 
received BCG therapy had an increased risk of recurrence. This finding was validated using 
SBC/EPICURO population. PLCB4 controls processes such as neural signaling, synaptic 
plasticity, and cellular growth(236), and separate mutations in PLCB4 have been linked to 
leptomeningeal melanocytic tumors and uveal melanoma(237, 238). The mechanisms 
underlying the association between PLCB4 and bladder cancer is not clear, though PLCB4 is 
expressed in bladder tissue(235). In addition, a variant (rs6056401) located in PLCB4 has been 
shown to be protective against anxiety disorders with nominal significance(239). Because 
currently depressed bladder cancer patients show worse overall survival, we speculate that 
there is a potential relationship between mental health, genetics, and bladder cancer. More 
research is needed to further understand this relationship.  
      This is the first study to examine the association between SNPs in the dopamine pathway 
and bladder cancer clinical outcomes leveraging the largest on-going bladder cancer study in 
the United States with rich data. Another significant strength of this study is that a total of eight 
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variants were validated using an independent population (SBC/EPICURO). A potential 
limitation of this study is the small sample size for the treatment stratification analyses. For 
example, only 260 patients (70 of those 260 patients experienced progression) of the 503 
NMIBC patients received BCG therapy. To offset this potential issue, we used a lower p-value 
cut-off for the discovery phase analysis. Further studies are needed to fully understand the 
mechanism of these variants on bladder cancer clinical outcomes. The findings from this novel 
study has the potential to stratify patients who are at higher risks for poor bladder cancer 
clinical outcomes and potentially be used to direct treatment options.  
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Chapter 5. Conclusions and Future Directions 
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      This dissertation identified sociodemographic and clinical determinants of QOL in breast 
and lung cancer patients. Specifically, when examining sociodemographic factors, smoking, 
marital status, and education were predictors of physical and mental QOL in both lung and 
breast cancer patients. Further, a racial disparity existed when examining physical QOL in 
breast cancer patients. When examining how determinants of poor physical QOL were 
distributed among races, determinants of poor QOL were more prevalent among Hispanic and 
Black patients than whites. These results could be used to target individuals for interventions 
with the goal of improving physical and mental QOL. In addition, targeted interventions could 
hopefully bridge the gap in racial disparities of QOL in breast cancer patients. Finally, we 
identified eight SNPs in the dopamine pathway genes that were associated with bladder cancer 
outcomes (recurrence or progression). These results could potentially be used to identify 
patients at risk for poor outcomes of bladder cancer and could also potentially aid in treatment 
decisions by genetically testing patients.  
      Chapter 2 and Chapter 3 of this dissertation focused on determinants of QOL in lung 
cancer patients and breast cancer patients. An interesting determinant from the research on 
lung cancer is that stage at diagnosis increased the risk of poor PCS or MCS more than any 
other determinant examined. It is very likely that those with later stage disease are 
experiencing worse symptom burden and higher mortality which could decrease QOL scores.  
Similar determinants were associated with PCS and MCS scores in breast and lung cancer 
patients which highlights that there is similarity in the determinants of QOL in cancer patients. 
While cancer sites have their own deficits in QOL and disease struggles (for example, lung 
cancer patients report very low QOL scores compared to other sites), this provides support that 
interventions could have wide applicability and target multiple cancer sites and do not 
necessarily have to be cancer site specific or could have components that are cancer site 
specific. For example, as education level increased average PCS and MCS scores increased 
as well in both populations. It is thought that education level can act as a proxy for SES, and 
research supports that baseline SES status is associated with poor QOL in lung cancer 
98 
 
patients(240) and breast cancer survivors(200). Another determinant associated with QOL in 
both populations was marital status. Specifically, divorced patients reported lower PCS and 
MCS scores in the lung cancer population and the “Other” group (which includes divorced 
patients) in marital status reported lower PCS and MCS scores in the breast cancer population. 
As stated previously, marital status itself is a prognostic factor for cancer survival(186). This 
relationship is likely due to a lack of social support and it makes sense that a lack of social 
support would negatively impact QOL scores as well.  
      An interesting finding in Chapter 4 was the racial disparities that existed in QOL scores in 
breast cancer patients. It is well known that racial disparities exist in breast cancer clinical 
outcomes(60, 177, 178) and we found consistent results in our study population. We also 
showed that lower PCS scores were associated with lower overall survival. In this dissertation 
chapter we discovered that Hispanic and Black patients reported lower PCS scores compared 
to White patients and we aimed to further understand determinants that may impact this 
finding. Ideally, by understanding which factors affected QOL scores and were more 
concentrated in Hispanics and Blacks (groups that reported lower PCS scores) one could more 
specifically identify patients for interventions and possibly improve survival. Marital status was a 
determinant that was associated with QOL scores as discussed above in the previous 
paragraph. Black and Hispanic patients had higher proportions of “Never Married” and patients 
in the “Other” group (separated, divorced, and widowed) as well as slightly lower PCS scores in 
those groups compared to the other races. Other determinants associated with QOL that have 
disproportionate patterns in racial groups included number of positive lymph nodes. It is also 
possible that QOL differences reported by races are also due to differences in disease severity 
at diagnosis which should also be taken into consideration. Taking all of these factors together, 
you could potentially be able to more specifically target individuals to improve QOL in the clinic. 
Even potentially developing an easy to use checklist that includes these determinants for 
nurses and clinicians to better identify patients.  
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      In Chapter 2 of my dissertation, we focused on determinants of QOL and included a 
genetic component to our QOL study and examined genetic polymorphism in the p38 MAPK 
pathway and QOL scores as well as survival. It is difficult to state exactly what is occurring 
mechanistically between p38 MAPK and QOL. One hypothesized mechanism of action is that, 
as stated earlier, peripheral circulating pro-inflammatory cytokines activate the p38 MAPK 
pathway(131). It is possible that a higher levels of pro-inflammatory cytokines caused by 
existing depression(112, 241), the lung tumor itself(242), or from patient factors such as 
cigarette smoking(243) are excreting pro-inflammatory cytokines which in turn are activating 
the p38 MAPK pathway and is therefore producing more pro-inflammatory cytokines. Cytokines 
are large molecules but are able to cross the blood-brain barrier into the brain through leaky 
regions or through specialized transport molecules(112). It is possible that the pro-inflammatory 
cytokines are accessing the brain and inducing sickness behavior (which has many overlapping 
symptoms of depression) by altering neurotransmitters such as dopamine, norepinephrine, and 
serotonin(112). It is not entirely clear how the variant we validated (MEF2B: rs2040562, 
associated with an increase risk in poor mental health) mechanistically is involved, although as 
stated before increased expression of this gene is associated with depression in cancer 
patients(156) and is also associated with obsessive-compulsive disorder (OCD)(244) indicating 
a role in mental health. Depression is a domain of the MCS score from the QOL measure we 
used in this study and overall is an important domain of QOL.  
      Another possibility regarding the mechanism between the p38 MAPK pathway and QOL 
relates to activation of this pathway in the brain, leading to downstream negative effects. 
Research shows that the p38 MAPK pathway is highly activated in neurons in the brain with 
important roles in learning, memory, and synaptic plasticity(245, 246). For example, p38 MAPK 
can alter neurotransmitter function through the serotonin transporter SERT (encoded by 
SLC6A4)(153). Activation of SERT leads to the reuptake of serotonin and has been associated 
with many mood disorders such as depression, obsessive compulsive disorder, and suicide. 
Further studies have also found that elevated pro-inflammatory cytokines such as IL-1 and 
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TNF-alpha (activators of the p38 MAPK pathway) are associated with decreased cerebrospinal 
fluid (CSF) concentrations of serotonin metabolites, indicating activation of SERT(247). What is 
also very interesting, is in Chapter 4 of my dissertation I examined variants in the dopamine 
pathway and bladder cancer clinical outcomes. The dopamine pathway was of interest due to 
its associations with depression. Research evidence supports that activation of the p38 MAPK 
pathway can produce cytokines in the brain that then affect the reuptake of neurotransmitters 
such as dopamine(248). Specifically, activation of MAPK pathways has been shown to affect 
the dopamine transporter (increase reuptake of dopamine) in cell lines, and this effect is 
blocked when using MEK inhibitors(249). This provides evidence of the complex nature of the 
biological role of QOL. This also provides rational for completing a more systemic 
comprehensive genetic analysis including all relevant pathways of QOL across multiple cancer 
sites.  
      In Chapter 4 of my dissertation, we validated eight genetic variants from the dopamine 
pathway with bladder cancer clinical outcomes in NMIBC. Three variants in SYT1 were 
associated with overall progression, one variant in SLC1A1 was associated with progression in 
patients that received TUR-only, one variant in PLCB4 was associated with recurrence in 
patients that received BCG therapy, and one variant in CAMK2A and two variants in SYT1 
were associated with progression in patients that received BCG therapy. It is not clear if 
mechanistically dopamine variants are affecting bladder cancer outcomes through peripheral 
action or from action in the brain that results in a change in clinical outcomes through mood. 
Peripherally, dopamine that is secreted has been shown to have anti-tumor effects through 
blocking angiogenesis and therefore stopping tumor growth(215). While studies have not been 
completed examining bladder cancer specifically, dopamine receptors are present in the 
bladder(116) and genes from this dissertation with validated variants are expressed in bladder 
tissue (specifically SLC1A1, CAMK2A, and PLCB4)(235). And the results of this chapter 
provide support for further functional studies to understand how and if dopamine is acting in the 
bladder. Conversely, it is possible that variants in the dopamine pathway are acting in the brain 
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and impacting the processing of dopamine. Which coupled with or without environmental 
factors and stressors could lead to depressive symptoms and poor clinical outcomes. Stress 
and depression have both been associated with clinical outcomes such as progression of 
cancer(104). 
      When taking these genetic results into a larger context, it is possible that validated variants 
such as the ones discovered in Chapter 2 and Chapter 4 could be used in the future for 
genetic testing of patients and become a component of personalized medicine. Research 
already supports a genetic component to depression(250) as well as variants that have been 
identified that are associated with a decrease response to antidepressant therapy(112), which 
further supports a genetic component to QOL (as depression is a domain of QOL) and stresses 
the importance of direct clinical use. It is important to mention that the relationship between 
genetic variants and phenotypes such as QOL or depression are associations. QOL has a 
complex etiology, as has been shown in this dissertation, but genetics plays an important role 
and it is very possible that QOL is polygenic. Which means that more comprehensive analyses 
are need that also include variants known to be associated with domains of QOL, such as 
depression. In the future, if personalized medicine reaches the point where patients are tested 
for common genetic variants, the genetic results from this dissertation (with further validation) 
could potentially be included. For example, lung cancer patients (or with further studies, 
patient’s with other cancers as well) would be tested for a panel of polymorphisms that have 
been validated for associations with QOL. Then based on those results and combined with host 
determinant information, specialized interventions would be used. In terms of mental QOL 
interventions, antidepressant therapy could be prescribed in addition to talk therapy and social 
support groups. The results from Chapter 4, with further validation, could identify patients at 
risk for progression of bladder cancer. In the clinic, clinicians could use this genetic information 
to better identify patients in need of more aggressive therapy or treatment options. This could 
include frequent cystoscopies to look for progression of bladder cancer or more aggressive 
treatment options such as cystectomies.   
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      A striking result from my dissertation in Chapter 2 is the association between low PCS or 
low MCS in lung cancer patients and an increased risk of death, even after controlling for stage 
at diagnosis. Our findings were not just seen in lung cancer patients, we also saw this 
relationship in Chapter 3 between PCS score and overall survival in breast cancer patients. 
Given how many domains go into determining a QOL score, there are many hypothesized 
reasons for this relationship. For example, patients that report poor QOL scores may be less 
likely to follow medical treatment fully to gain maximum benefit and therefore could shorten 
survival. Research has shown that patients that report low QOL are less like to adhere to 
medical advice compared to patients who report better QOL(26, 251). The worse a patient is 
feeling in terms of QOL (for example the more depressed they are, the more they are 
experiencing physical limitations) they could be less likely to attend treatment appointments for 
fear of feeling worse or are less likely to be willing to participate in things that may improve their 
QOL. Further, domains of QOL such as depression also have been associated with poor 
cancer survival(252). Depression is very prevalent in the general population(252). If a person is 
already dealing with depression or more prone to depressive episodes, it is possible they would 
report lower QOL scores in the mental domain. Finally, another possible explanation for the 
relationship between QOL and cancer survival is that QOL may be a proxy for SES(200). For 
example, studies have shown that SES at baseline is associated with QOL in lung cancer 
patients(240). Further, evidence also supports that a higher SES is associated with better 
survival in cancer patients(253). Therefore it is a possibility that cancer patients with a higher 
SES would report higher QOL and show better survival. It is very clear that many factors play 
into QOL and the relationship with survival in cancer patients. It is not likely one factor that is 
underlying this relationship.  
      The ultimate goal of this dissertation is to understand determinants of QOL with the hopes 
of in the future improving QOL and therefore improving survival. When examining ways of 
improving QOL, the idea is to be able to identify patients at high risk of poor QOL or who are 
reporting a poor QOL and identify the factors that may be impacting their QOL. Then be able to 
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intervene early during a cancer diagnosis with the goal of improving QOL. Determinants of 
QOL can be thought of a modifiable and non-modifiable. Examples of modifiable factors would 
be determinants such as smoking status or alcohol usage as well as factors that are 
considered to be modifiable but are not likely to change dramatically (such as marital status or 
education level). Examples of non-modifiable factors are genetics, age, and past medical 
history. When thinking in terms of clinical interventions, the obvious target would be to 
intervene in modifiable factors with the hopes of improving QOL. An example of this would be 
smoking cessation programs. But there are also non-modifiable factors (or factors that are not 
easily modified) that should be taken into consideration. For example, it is not easy to modify 
marital status. If a patient is single or widowed it is not likely or easy to change that situation. 
And those patients could be lacking social support which could negatively impact QOL. What 
could potentially be done is to target those patients for support groups or peer mentoring 
groups with the goal of improving social support. Because of how multifaceted QOL is and the 
many determinants that impact QOL scores, interventions should be comprehensive and multi-
faceted as well. Even when intervening in patients with a devastating diagnosis, such as stage 
IV lung cancer that is not curative, the goal would still be to prolong survival by improving QOL. 
Examples of promising interventions include web based that are completed by the patient at 
home(254) and interventions that target QOL and domains of QOL (such as fatigue, body-
image, stress, anxiety, and depression)(255). Our results provide even more support for the 
importance of these interventions and gives detailed determinant information that could be 
used to identify patients that could be approached for interventions. 
      In a clinical setting, QOL scores could be implemented in a patient’s medical chart with 
easy access for the clinician (scores could be provided with general patient summary 
information). Research supports that QOL scores implemented in a clinical setting have 
additional benefits of improving patient-physician communication, especially around sensitive 
subjects as well as non-medical concerns(256, 257). As stated in previous studies, in order for 
this to be efficient it is imperative that easy to use and interpret measures are used(162). The 
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SF-12v1 that was used for this dissertation was only 12 questions and was easy for patients to 
complete. In addition, it was grouped together with additional patient entry information 
questionnaires, which increases the ease of completing the questionnaire as it becomes part of 
routine paperwork. Because of the strong association between QOL and survival, it is also 
imperative to perform targeted interventions on vulnerable patients that are identified in a 
clinical setting because of the potential to be cost effective. Patients that have improved QOL 
that go on to have improved outcomes could require less frequent and less expensive medical 
treatment. Further, QOL assessments should be completed regularly at clinic visits to follow 
trends of QOL and identify patients who may be having issues that weren’t present at baseline 
measurement(123). 
      Future directions include an even more in-depth analysis of determinants of QOL. For 
example, obtaining information on physical activity level of patients and sitting time could aid in 
specific areas that could be targeted for intervention studies. For the genetic analysis in bladder 
cancer patients, conducting further functional studies on the validated SNPs will be needed to 
find the molecular mechanisms underlying the link between dopamine pathway and bladder 
cancer outcomes. Systemic study of genetic determinants of QOL and their impacts on patient 
outcomes will be a major effort in the future.     
      Taken together, our study provides a comprehensive overview of QOL in lung and breast 
cancer patients and supports a role of QOL-related genetic variations on bladder cancer patient 
outcomes. The results support that QOL is a crucial component of patient care.  
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Appendix: Supplementary Tables 
 
Supplemental Table 1.  Association of Host Characteristics and PCS Scores 
Host Characteristic PCS<50 PCS≥50 OR (95% CI) P Value 
Age (Continuous) 4376 1329 1.00 (1.00-1.01) 0.246 
Sex     
Male 2295 735 1.00 (Ref)  
Female 2081 594 1.09 (0.95-1.26) 0.215 
Education     
< High School 596 102 1.00 (Ref)  
High 
School/Vocational/AA 
2603 687 0.76 (0.60-0.97) 0.026 
College Degree 1177 540 0.50 (0.39-0.64) 8.7x10-8 
Alcohol Use     
Never 1914 423 1.00 (Ref)  
Former 909 159 1.11 (0.90-1.37) 0.343 
Current 1553 747 0.50 (0.43-0.58) 1.0x10-16 
Smoking Status     
Never 690 298 1.00 (Ref)  
Former 2813 839 1.34 (1.11-1.61) 0.002 
Current 873 192 1.81 (1.43-2.31) 1.3x10-6 
Past Medical History     
Yes 3733 1080 1.00 (Ref)  
No 643 249 0.75 (0.63-0.90) 0.002 
Marital Status     
Married 3164 1026 1.00 (Ref)  
Widowed 453 109 1.19 (0.93-1.53) 0.166 
Separated  24 6 1.10 (0.42-2.86) 0.850 
Divorced 455 95 1.36 (1.06-1.74) 0.014 
Never Married 280 93 0.96 (0.74-1.26) 0.787 
Race     
White 3631 1127 1.00 (Ref)  
Hispanic 178 55 0.95 (0.68-1.33) 0.763 
Black 346 68 1.18 (0.88-1.57) 0.268 
Asian/Pacific Islander 145 56 0.87 (0.61-1.22) 0.409 
Other 76 23 1.00 (0.60-1.65) 0.995 
Past Treatment     
Yes 1400 211 1.00 (Ref)  
No 2976 1118 0.40 (0.32-0.50) 4.4x10-16 
Histology     
Non-Small Cell     
Adenocarcinoma 2093 731 1.00 (Ref)  
Squamous Cell 720 190 1.41 (1.16-1.72) 0.001 
Large Cell 155 36 1.36 (0.92-2.02) 0.122 
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Non-small cell 
carcinoma –         
non-specified 
727 186 1.14 (0.94-1.39) 0.178 
Small Cell 519 105 1.34 (1.05-1.71) 0.018 
Other 162 81 0.93 (0.68-1.27) 0.641 
Stage     
I 338 226 1.00 (Ref)  
II 114 87 0.79 (0.56-1.11) 0.167 
III 612 270 1.45 (1.15-1.84) 0.002 
IV 1276 322 2.79 (2.23-3.50) <1.0x10-63 
Unknown 2036 424 2.02 (1.58-2.58) 1.7x10-8 
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Supplemental Table 2.  Association of Host Characteristics and MCS Scores 
Host Characteristic MCS<50 MCS≥50 OR (95% CI) P Value 
Age (Continuous) 3255 2450 0.98 (0.98-0.99) 5.0x10-8 
Sex     
Male 1631 1399 1.00 (Ref)  
Female 1624 1051 1.41 (1.26-1.59) 6.8x10-9 
Education     
< High School 483 215 1.00 (Ref)  
High 
School/Vocational/AA 
1902 1388 0.58 (0.48-0.70) 9.4x10-9 
College Degree 870 847 0.50 (0.41-0.61) 1.8x10-11 
Alcohol Use     
Never 1360 977 1.00 (Ref)  
Former 668 400 1.20 (1.02-1.40) 0.025 
Current 1227 1073 0.90 (0.80-1.02) 0.107 
Smoking Status     
Never 483 505 1.00 (Ref)  
Former 2089 1563 1.40 (1.19-1.65) 3.8x10-5 
Current 683 382 1.69 (1.38-2.06) 2.9x10-7 
Past Medical History     
Yes 2777 2036 1.00 (Ref)  
No 478 414 0.77 (0.66-0.90) 0.001 
Marital Status     
Married 2348 1842 1.00 (Ref)  
Widowed 311 251 0.91 (0.75-1.11) 0.362 
Separated  22 8 1.84 (0.80-4.26) 0.153 
Divorced 359 191 1.24 (1.02-1.50) 0.029 
Never Married 215 158 0.94 (0.75-1.18) 0.606 
Race     
White 2718 2040 1.00 (Ref)  
Hispanic 133 100 0.95 (0.72-1.26) 0.726 
Black 258 156 1.00 (0.81-1.25) 0.975 
Asian/Pacific Islander 92 109 0.72  (0.54-0.98) 0.035 
Other 54 45 0.88 (0.58-1.33) 0.552 
Past Treatment     
Yes 971 640 1.00 (Ref)  
No 2284 1810 1.00 (0.84-1.19) 0.985 
Histology     
Non-Small Cell     
Adenocarcinoma 1547 1277 1.00 (Ref)  
Squamous Cell 519 391 1.12 (0.95-1.31) 0.173 
Large Cell 111 80 1.00 (0.74-1.36) 0.992 
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Non-small cell 
carcinoma – non-
specified 
545 368 1.10 (0.94-1.29) 0.244 
Small Cell 408 216 1.32 (1.09-1.59) 0.004 
Other 125 118 0.99 (0.75-1.31) 0.954 
Stage     
I 252 312 1.00 (Ref)  
II 85 116 0.86 (0.61-1.20) 0.361 
III 495 387 1.55 (1.24-1.94) 9.8x10-5 
IV 943 655 1.76 (1.43-2.16) 6.2x10-8 
Unknown 1480 980 1.81 (1.45-2.27) 2.0x10-7 
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Supplemental Table 3. Association Between p38 MAPK Variants and PCS/MCS Scores 
    Discovery Phase   
    PCS   
Gene: SNP Model 
PCS <50 
WW/WV/VV 
PCS≥50  
WW/WV/VV 
*OR (95% CI) P Value 
TNFRSF1B: rs496888 Dom. 120/88/14 36/51/12 0.40 (0.21-0.75) 0.004 
MAPK11: rs909692 Dom. 83/110/28 20/62/17 0.35 (0.17-0.73) 0.005 
MAP2K6: rs2716191 Dom. 78/91/53 22/51/26 0.37 (0.19-0.75) 0.006 
MAP2K6:  rs2715812 Dom. 113/93/16 36/53/10 0.42 (0.22-0.78) 0.006 
MAP2K6:  rs2074028 Dom. 94/98/30 29/50/20 0.41 (0.21-0.79) 0.008 
MAP3K5:  rs11755484 Dom. 190/32/0 95/3/1 4.85 (1.50-16.02) 0.010 
MEF2B:  rs12459686 Rec. 72/118/32 34/43/22 0.36 (0.17-0.78) 0.010 
MAP2K6:  rs989681 Dom. 60/100/62 18/50/31 0.36 (0.16-0.79) 0.011 
MAP2K6:  rs2716227 Dom. 70/98/54 19/52/28 0.40 (0.19-0.83) 0.014 
MEF2B:  rs3761081 Add. 145/70/7 56/35/8 0.53 (0.32-0.88) 0.014 
MEF2A:  rs325381 Dom. 178/42/2 67/28/4 0.42 (0.21-0.85) 0.015 
MAP2K4:  rs1870584 Dom. 66/117/39 40/43/16 2.15 (1.12-4.12) 0.022 
MAP3K5:  rs9494569 Add. 67/118/37 37/55/7 1.75 (1.08-2.84) 0.023 
MAP2K4:  rs12942507 Dom. 93/102/27 52/38/9 2.05 (1.10-3.81) 0.023 
MAPK14:  rs13196204 Add. 159/56/7 64/28/7 0.54 (0.31-0.92) 0.024 
TNF:  rs1800629 Add. 174/43/5 72/22/5 0.51 (0.28-0.92) 0.024 
MAP2K6:  rs2521365 Dom. 114/81/27 41/47/11 0.51 (0.28-0.93) 0.028 
MEF2D:  rs1171556 Dom. 182/39/1 70/25/4 0.45 (0.22-0.92) 0.029 
MEF2A:  rs12593522 Add. 167/51/4 66/27/6 0.54 (0.31-0.94) 0.030 
MAP2K3:  rs1466314 Dom. 128/74/20 42/48/9 0.52 (0.29-0.95) 0.032 
MAP2K4:  rs8082185 Rec. 116/96/10 52/39/8 0.23 (0.06-0.89) 0.033 
MEF2D:  rs1750304 Dom. 184/38/0 70/26/3 0.47 (0.24-0.95) 0.035 
TNFRSF1B: rs17037696 Rec. 136/70/16 65/33/1 9.84 (1.14-85.33) 0.038 
MAPK11:  rs6010226 Add. 75/110/36 20/60/19 0.62 (0.40-0.98) 0.040 
TNF:  rs2009658 Dom. 148/65/9 73/25/1 1.99 (1.02-3.87) 0.043 
TNFRSF1B:  rs1061624 Rec. 77/81/64 34/48/16 2.17 (1.02-4.61) 0.043 
MAPK11:  rs2076139 Add. 124/80/18 66/31/2 1.71 (1.02-2.88) 0.044 
MAP2K4:  rs9303045 Add. 63/111/48 26/46/27 0.65 (0.43-0.99) 0.046 
MAP2K6:   rs9302900 Dom. 123/83/16 65/27/7 1.84(1.00-3.39) 0.049 
    MCS     
Gene: SNP Model 
MCS <50  
WW/WV/VV 
MCS≥50 
WW/WV/VV 
*OR (95% CI) P Value 
MAP2K3: rs1466314 Dom. 79/71/19 91/51/10 2.25 (1.31-3.87) 0.003 
TRAF2: rs3739942 Rec. 90/58/21 90/58/4 5.43 (1.55-18.95) 0.008 
TNFRSF1B: rs1061628 Rec. 58/91/20 54/66/32 0.41 (0.20-0.81) 0.011 
TNFRSF1A: rs4149578 Dom. 143/25/1 117/34/1 0.43 (0.22-0.83) 0.011 
MAP2K6A:  rs2715815 Add. 68\82\19 47\80\25 0.62 (0.41-0.93) 0.021 
MAP2K6:  rs9302900 Rec. 95\59\15 93\51\8 3.97 (1.21-13.01) 0.023 
MAP2K3:  rs9899521 Add. 111\51\7 80\59\12 0.60 (0.39-0.93) 0.024 
MAP2K6:  rs2028049 Rec. 76\63\30 69\70\13 2.61 (1.13-6.00) 0.024 
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MEF2A:  rs10902549 Dom. 55\78\36 31\82\39 0.51 (0.28-0.94) 0.031 
MAP2K6: rs6501328  Rec. 92/62/15 84/60/8 3.31 (1.11-9.90) 0.032 
MAP2K4: rs12942507 Dom. 83/63/23 62/77/13 0.56 (0.32-0.96) 0.034 
TRAF2: rs10781522 Rec. 60/71/38 55/82/15 2.18 (1.05-4.54) 0.037 
FAS: rs6586163 Dom. 40/87/42 25/92/35 0.49 (0.25-0.96) 0.037 
MAP2K6: rs11651488 Rec. 98/57/14 94/51/7 3.15 (1.07-9.30) 0.037 
MEF2A: rs325383 Rec. 78/68/23 86/59/7 2.83 (1.06-7.55) 0.038 
FASLG: rs10458360 Rec. 49/85/35 47/85/20 2.13 (1.04-4.38) 0.039 
MEF2B: rs2040562 Rec. 86/60/23 75/70/7 3.06 (1.05-8.92) 0.041 
TNFRSF1B: rs5745984 Dom. 156/13/0 150/2/0 5.34 (1.05-27.21) 0.044 
TNF: rs2009658 Rec. 113/47/9 108/43/1 9.58 (1.02-89.75) 0.048 
MAP2K4: rs8064513 Rec. 83/69/17 71/71/10 2.86 (1.01-8.08) 0.048 
Abbreviations: OR-Odds Ratio, Dom.-Dominant, Rec.-Recessive, Add.-
Additive   
*Adjusted for age, sex, race, education, marital status, alcohol use, smoking status, past medical history, prior 
cancer treatment, histology, and cancer stage 
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Supplemental Table 4. Association between Genetic Variants in the p38 MAPK Pathway 
and 5-Year Overall Survival  
  
 Model 
Dead 
WW/WV/VV 
Alive 
WW/WV/VV 
*HR (95% CI) P Value 
Model 
MST (Months) 
Plog-rank 
MAP3K5: rs3765259 Dom. 66/111/59 17/46/22 0.56 (0.40-0.79) 0.0008 
WW/WW+WV 
17.31/23.75 
0.053 
MAP2K6: rs817545 Rec. 55/116/65 27/41/17 1.70 (1.23-2.35) 0.001 
WW+WV/VV 
23.10/17.45 
0.152 
MAP2K6: rs4968791 Rec. 65/107/59 29/43/13 1.68 (1.20-2.35) 0.003 
WW+WV/VV 
23.75/17.45 
0.066 
MAPK11: rs909692 Rec. 75/125/35 28/47/10 1.82 (1.21-2.73) 0.004 
WW+WV/VV 
22.93/18.10 
0.180 
MAP2K6: rs2716195 Dom. 173/57/6 55/26/4 0.62 (0.44-0.88) 0.006 
WW/WV+VV 
21.32/26.74 
0.108 
TNFRSF1B: rs7552664 Rec. 144/80/12 47/28/10 0.39 (0.19-0.80) 0.011 
WW/WV+VV 
21.52/49.09 
0.030 
MAP2K6: rs6501328 Dom. 131/86/19 45/36/4 0.69 (0.51-0.93) 0.016 
WW/WV+VV 
23.03/21.59 
0.672 
MEF2B: rs12609573 Add. 68/116/52 33/38/14 1.28 (1.03-1.58) 0.023 
WW/WW+WV/WW+WV+VV 
30.55/21.49/18.37 
0.033 
MAPK11: rs6010226 Add. 74/117/44 21/53/11 1.29 (1.03-1.61) 0.026 
WW/WW+WV/WW+WV+VV 
22.44/24.51/16.99 
0.049 
MEF2B: rs12459686 Add. 87/115/34 19/46/20 0.79 (0.63-0.98) 0.032 
WW/WW+WV/WW+WV+VV 
18.37/23.06/33.94 
0.023 
MAP2K6: rs2715825 Rec. 105/110/21 30/40/15 0.53 (0.30-0.95) 0.033 
WW+WV/VV 
21.88/29.63 
0.065 
MEF2D: rs16837415 Dom. 205/30/1 79/6/0 1.69 (1.04-2.73) 0.034 
WW/WW+WV 
21.88/22.57 
0.278 
MAPK14: rs851006 Dom. 136/82/18 48/32/5 0.72 (0.53-0.98) 0.034 
WW/WV+VV 
21.88/22.34 
0.564 
MAP2K4: rs4791490 Rec. 145/86/5 48/30/7 0.22 (0.05-0.92) 0.039 
WW+WV/VV 
21.95/NA 
NA 
MEF2D: rs10159180 Dom. 62/123/51 33/34/18 1.44 (1.01-2.05) 0.041 
WW/WV+VV 
22.93/21.88 
0.102 
TNF: rs3093662 Dom. 203/30/3 79/6/0 1.54 (1.01-2.35) 0.046 
WW/WV+VV 
23.03/14.85 
0.040 
MEF2A: rs325383 Rec. 122/95/19 42/32/11 0.58 (0.34-0.99) 0.046 
WW+WV/VV 
21.52/34.66 
0.143 
MEF2D: rs16837408 Dom. 179/47/10 60/23/2 0.70 (0.49-0.99) 0.047 
WW/WV+VV 
19.09/37.95 
0.027 
Abbreviations: HR – Hazard Ratio, CI – Confidence Interval, Dom.-Dominant, Rec.-Recessive, 
Add.-Additive 
  
*Adjusted for age, sex, smoking status, surgery, chemotherapy, radiation, chemoradiation, 
performance status, histology, and cancer stage 
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